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Abstract 
Cell delivery is a promising treatment for cardiac repair; however it is limited by low 
cellular engraftment rates. With this limitation, we propose the use of fibrin microthreads 
as a mechanism for localized cellular delivery. The purpose of this project was to design 
a system to increase cell density on biological microthreads for use in cell assisted 
cardiovascular regeneration. The final design consisted of a dynamic seeding method 
paired with bundled microthreads, yielding 648±234cells/mm; indicative of a confluent 
cellular monolayer.   
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Part I. Proposal 
1.0 Introduction 
In a 2006 report by the American Heart Association, it was estimated that 1,200,000 
Americans each year will suffer from a new or recurrent heart attack, resulting in 
approximately 450,000 deaths 1. Heart attacks, or myocardial infarctions (MI), may be 
caused by tissue death due to ischemia. When tissue becomes ischemic, cardiomyocyte 
cell death occurs causing scar tissue formation. As a result, the mechanical properties of 
the heart are compromised, which may lead to erratic beating in the heart and a decrease 
in global heart function. This anomalous mechanical function can lead to poor blood flow 
and potential heart failure.  
 
In the field of cardiovascular regeneration, researchers are continuously working on new 
technologies and improving old ones. Recently, cell based cardiac repair has been 
proposed as a possible treatment for MI.  In particular human mesenchymal stem cells 
(hMSCs) have generated a great deal of excitement. However, although research is 
persistent, there are still many limitations. Examples of such limitations in the field 
include the quantity of cells delivered to the infarcted region and the engraftment rate of 
those cells into the surrounding tissue.  In general, low engraftment rates (6-12%) 2 can 
be attributed to non-localized cell delivery and cell leakage. Although significant 
advances using cells have been made in regeneration of the heart and blood vessels, these 
limitations require further investigation.  
 
The purpose of this project was to design a system to increase cell density on biological 
microthreads for use in cellular assisted cardiovascular regeneration. These microthreads 
can be used to deliver stem cells that may allow for the regeneration of ischemic tissue. 
These microthreads should maximize the quantity of cells that can be delivered given 
dimensional constraints of the device.  
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To increase the quantity of cells attached to biological microthreads an initial 
investigation of current literature was completed. This literature review compiled a 
background on the problem of myocardial infarction and heart failure followed by an 
analysis of cell based cardiac repair as a method of regenerating the heart post-MI. 
Within the category of cell based cardiac repair, several varieties of cells were 
investigated for cardiac applications; however hMSCs were found to be the most 
plausible cell type for this project. Following the selection of hMSCs as the cell type, 
cellular delivery options were considered. It was determined that biological microthreads 
were the best platform for cellular delivery as they can be employed to localize cellular 
delivery to the site of ischemia, potentially solving the low engraftment rate limitation 2-4. 
The selection of fibrin microthreads over other biological microthreads was made 
because fibrin is a natural biomaterial that is biocompatible, bioresorbable, and essential 
in normal wound healing 5. Finally, various techniques to increase cellular attachment, 
such as physical surface alterations, surface adhesion molecules, and cell seeding 
techniques, were explored. 
 
In order to devise the best method to increase stem cell density on biological 
microthreads, an iterative design process followed the literature review. As a part of the 
design process, constraints, objectives, and functions that the device must follow were 
consolidated. In addition, various techniques to increase cell density on biological 
microthreads such as physical surface alterations, surface adhesion molecules, and cell 
seeding techniques were compared via morphological charts and evaluation matrices for 
their ability to fulfill the client statement. 
 
Based on the design analysis, experiments were conducted showing that increased hMSC 
density on fibrin microthreads could be obtained by altering the seeding technique and 
physically altering the surface. Increased hMSC density on the fibrin microthreads was 
obtained with a dynamic (rotational) seeding, as compared to the current standard of 
static (droplet) seeding. Additionally, physical surface alterations, which were 
accomplished by bundling fibrin microthreads, also led to increased hMSC density on the 
fibrin microthreads. After further experiments, it was found that the optimum number of 
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fibrin microthreads per bundle was ten while the optimum seeding duration was 24 hours. 
When bundles of ten fibrin microthreads were rotationally seeded for 24 hours, a 
confluent monolayer of hMSCs could be obtained on the microthreads. To prove that 
fibrin microthreads could be used as a cellular delivery device, hMSC seeded bundles of 
ten microthreads were sutured fully through the heart, revealing that cells were still 
present on the microthreads following suturing. Results of this experiment were 
noteworthy because it indicated that hMSCs were not sheared off of the fibrin 
microthreads upon entry into the epicardium of the heart. In conclusion, rotationally 
hMSC seeded bundles of ten fibrin microthreads are an exciting and novel technique for 
localized cellular delivery and may allow for cardiac regeneration in the future.
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2.0 Literature Review 
2.1 The Heart 
The heart is a dual pump situated in the thoracic cavity where it is responsible for 
pumping blood to both the systemic and pulmonary circulations. As a part of the 
circulatory system, the heart works in conjunction with blood vessels to pump blood 
throughout the entire body. Blood itself serves as a transport medium while the vessels 
are the passageways through which blood travels to different organ systems.6 In systemic 
circulation, the oxygenated blood travels throughout the body depositing oxygen to 
power cellular processes. 
 
The heart is a vital organ that must function properly in order to sustain life. Should 
adverse events arise within the heart, such as arrhythmias, blocked arteries, or ischemia, 
serious health complications can occur.  
 
2.2 Myocardial Infarction and Heart Failure 
It is estimated that each year 1,200,000 Americans suffer from a MI, contributing to 
450,000 deaths each year from heart failure 1.  Heart failure due to MI can occur when 
approximately  25% of the ventricle’s cardiomyocytes die 7. In the United States, the 
estimated direct cost for heart failure in 2006 was $29.6 billion1. Increasingly complex 
medical therapy has decreased morbidity and mortality associated with heart failure. 
However, on any given day, about 4,000 people are waiting for a heart transplant, but 
with donor shortages there are only enough donor hearts to provide about 2,000 
transplants each year 8. Because of the alarming number of deaths each year due to heart 
failure, researchers are developing new methods of cardiac regeneration. Although 
research for new and improved treatments is persistent, there are still many limitations in 
cardiovascular regeneration, primarily due to the inability of adult cardiomycocytes to 
adequately proliferate and generate new myocardial tissue to repair the heart. 
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2.3 Cell-Based Cardiac Repair 
Current treatment options for heart failure are limited. Traditional approaches include the 
use of medication and surgery to increase blood flow to the heart 1.  In response to the 
emergent issue of cardiovascular diseases in the United States, alternative methods to 
treating diseases such as MI and heart failure have been developed. Recently, the area of 
cell based cardiac repair has been given a great deal of attention. Although cell based 
cardiac repair was not initially accepted, the evidence for cell based therapies has shown 
that implanted cells could create new tissue and improve function of the failing heart 9.  
 
In the last few decades, a number of different cell based cardiac repair therapies have 
been developed. This area of research first began with the use of skeletal myoblasts. 
Original expectations for skeletal myoblasts were that the cells would transdifferentiate 
into cardiomyocytes; however it is clear that myoblasts remain committed to form mature 
skeletal muscle in the heart 10. Following the use of skeletal myoblasts, other cell lineages 
were explored such as endothelial progenitor cells (EPCs), embryonic stem cells, as well 
as adult stem cells. Although EPCs and embryonic stem cells have advantageous qualities 
in cardiac bioengineering applications, each possess drawbacks. For example, EPCs are 
difficult to harvest and their homing capacity is often affected upon expansion 11. On the 
other hand, the use of embryonic stem cells poses ethical issues.  
 
The use of adult stem cells for cardiac regeneration is advantageous due to their inherent 
cellular plasticity. Adult stem cells can be found in all mature humans. It is a cell that is 
undifferentiated, meaning that it has not yet generated structures or manufactured 
proteins characteristic of a specialized cell type 12, 13. These cells can be found among 
differentiated cells in a tissue or organ, can renew themselves, and can differentiate to 
yield the major specialized cell types of the tissue or organ, such as neural 14, bone, 
cartilage, fat, muscle, marrow stroma 15, 16digestive tract 12, and cardiomyocytes 17. Their 
primary endogenous function is to maintain and repair the tissue in which they reside 18-
20
.  
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2.4 Human Mesenchymal Stem Cells 
Among various adult stem cells, human mesenchymal stem cells are the best candidate 
for cellular delivery to cardiac tissue. They can be easily obtained from the femoral bones 
of patients for clinical applications 21 and then isolated, propagated in culture, and frozen 
for preservation without losing their capacity to form a variety of cell types, including 
cardiomyocytes 17. Until recently, cardiac myocytes were considered to be terminally 
differentiated. Recent evidence suggests that cardiac myocytes have the potential to enter 
the cell cycle 22, 23 and that stem cells may be useful in increasing myocyte mass through 
either differentiation into myocytes 24 or by inducing native myocytes to proliferate 25.  
 
In addition to increasing myocyte mass, studies involving hMSCs have indicated other 
beneficial effects of hMSCs in cardiac applications. In animal models, introduction of 
mesenchymal stem cells have been used to demonstrate that stem cells delivered post-MI 
improve angiogenesis 26 and myocardial wall movement 27. One study demonstrated that 
marrow-derived stromal cells increased perfusion in a mouse hindlimb ischemia model 26. 
Another study showed that hMSCs may also play a role in angiogenesis in diseased 
hearts; for example, transplanted hMSCs have increased capillary density in a rat model 
of dilated cardiomyopathy 28. 
2.5 Delivery Options  
One barrier to achieving the potential benefits of hMSCs as agents for cardiac repair, is 
the delivery technique. In an attempt to restore cardiovascular function post MI in the 
human heart, vast quantities of hMSCs need to be transported to the infarcted area of the 
heart tissue. The average left ventricle contains approximately 4 billion cardiomyocytes. 
Heart failure due to MI can occur when approximately 25% of the ventricle, or one 
billion, cardiomyocytes die. Current technology cannot achieve the goal of complete 
regeneration, however substantial physiological benefit, or repair, can be derived from 
the delivery and engraftment of cells into the infarcted heart 7.  
 
Due to the necessity of engrafting a large enough quantity of hMSCs into the heart, 
different cell delivery options were investigated. A common technique for cellular 
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delivery to the heart is injection. There are several methods of injection; including 
intramyocardial injection, intracoronary injection, and intravenous injection. 
Intramyocardial injection is not a viable technique because it can result in a loss of cells 
to the injection site, as well as lead to hypoxia and stress, thereby resulting in a 
significant quantity of cell death 29. Similar to intramyocardial injection, intracoronary 
injection is not beneficial because there is a risk of myonecrosis, or tissue death, if cell 
quantity and infusion characteristics are not precisely determined. In addition, 
intracoronary injection is also correlated to a decrease in the coronary blood flow in the 
heart 3. A third approach used to inject hMSCs is intravenous infusion.  Although this 
appears to be the simplest and least invasive tool for cell delivery, it poses problems with 
the homing of the cells to the proper organ 3.  The concept of the cells homing to non-
cardiac organs and the lack of cell engraftment deems this means of delivery 
inappropriate for this particular project. 
 
Targeting of cell delivery is essential for localized myocardium repair. If stem cells are to 
have a maximal effect, they must be concentrated at the site of injury. It has been 
reported that, in general, hMSCs are attracted to sites of injury 30-33 and specifically to 
sites of infarction 34, 35. Although hMSCs are attracted to sites of infarction, the mode of 
delivery is essential because the success of cellular based regeneration is dependent on 
the quantity of cells delivered and engrafted to the area of damage 24. If cell delivery is 
not localized or if cells leak from the delivery site, such as through the injection of cells, 
low engraftment rates (3-12%) will result 2-4. Therefore, improved engraftment rates can 
be accomplished through the direct application of cells to the myocardial infarction 24, 
such as through suturing the cells into the heart on biological microthreads.  
 
2.6 Microthreads  
To deliver the hMSCs to the infarcted region of the myocardium, a proper platform must 
be selected. Previous research has shown that biological microthreads can be used as a 
cellular platform 5, as they have the ability to be woven or braided in order to create a 
larger and stronger base.  Additionally, biological microthreads also often mimic the 
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structure of natural tissue, are biocompatible, biodegradable and mechanically strong 5.  
Finally, biological microthreads are known to aid in cell orientation and migration, which 
is a key aspect in tissue regeneration 5. There are various types of biological 
microthreads, including collagen and fibrin. However, PhD candidate Jacque Guyette 
suggested the use of fibrin microthreads, as opposed to collagen microthreads, based on a 
higher hMSC affinity for fibrin microthreads. This affinity can likely be attributed to the 
properties of the wound healing process and hMSCs’ affinity for sites of injury 30-33; 
fibrin is found in the initial stages of wound healing, whereas collagen is found in the late 
stages of wound healing 36.  
 
2.6.1 Fibrin Microthreads 
Fibrin has the potential to be used as a scaffold to deliver cells to wound sites. The 
ischemic damage caused by myocardial infarction and heart failure can be modeled as a 
wound. The first step in the wound healing process is comprised of the formation of a 
fibrin, plasma-derived protein matrix, working concurrently with other extracellular 
matrix (ECM) proteins and cytokines 37. Fibrin is an appealing natural biomaterial 
because it is biocompatible, bioresorbable, and essential in normal wound healing. In 
vitro studies indicate that fibrin can support the growth, migration, and differentiation of 
mesenchymal stem cells 38. Fibrin biomaterials are able to form microenvironments that 
mimic physiologic conditions that are essential for cells.  
 
In addition to the wound healing properties of fibrin, it has been demonstrated that the 
strength of fibrin microthreads over fibrin gels allows for assembly into bundles of fibrin 
microthreads that promote cell attachment and proliferation in a highly aligned scaffold 
for tissue regeneration 5. Hydrated microthreads are roughly cylindrical and averaged 100 
µm in diameter. These fibrin microthreads can be assembled into larger scale tissue 
constructs to direct cell alignment and migration for tissue regeneration. Typically when 
cells are applied to the fibrin microthread bundles, they align longitudinally with the long 
axes of all the microthreads and in the grooves between adjacent microthreads 5.  
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Furthermore, fibrin microthreads have improved structural and mechanical properties 
relative to other fibrin matrices, such as fibrin hydrogels. Maintaining the mechanical 
integrity of the microthreads throughout cell seeding and cell culture is critical for 
microthread transportation, arrangement into larger structures, and ease of implantation.                                    
2.7 Increasing Cell Density, Cell Attachment, and Cell Quantity 
A current limitation of fibrin microthreads as a platform for cellular delivery is the low 
density of hMSCs attached to the microthreads. To increase the attachment of hMSCs to 
fibrin microthreads, a variety of methods, including physical surface alterations, cellular 
adhesion molecules, and seeding technique, were reviewed. 
2.7.1 Physical Surface Alterations 
Physical surface alterations are able to influence cellular density 39. The distribution, 
adhesion, proliferation and differentiation of cells are highly regulated depending 
partially on the cellular orientation and surface contact 40. Cellular density can be 
manipulated when cells align on a surface and fill in the gaps and grooves 5. Such 
parameters may be of particular importance in cell types that are multipotent, such as 
hMSCs. Through the creation of microgrooves on the surface of implanted devices, the 
activity of the cell can be monitored and regulated. Not only do the microgrooves control 
the spatial organization of cells, but also affect the activities of cells, leading to the 
expression of different genes, which may lead to increased cellular attachment 39. 
 
Microgrooves in the scaffold are a potential method for altering the surface and 
improving cell adhesion. In one study, imprints were made in chitosan–collagen–gelatin 
blended membranes and the morphology and growth of hMSCs were observed 39. In this 
study, the growth of hMSCs was affected by the spacing size between adjacent ridges. 
The proliferation of the hMSCs on 200 µm patterned membranes was more than four 
times of that on 20 µm patterned membranes 39. This result supports the idea that the 
growth of hMSCs is limited by the size of the microgroove.  
 
Fibrin microthreads can be bundled to make intricate structures with microgrooves 
between the microthreads. Hydrated fibrin microthreads average 100 µm in diameter 5. 
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The microthread diameter is a function of the extrusion tube diameter and can be 
increased to optimize microgroove size and distance between the microthreads. 
Therefore, if bundled, fibrin microthreads may provide a topography that induces 
attachment. Through the bundling of these microthreads into organized structures, cell 
orientation and attachment can be manipulated.  
 
2.7.2 Chemical Surface Alterations: Cell Adhesion Molecules 
Cellular attachment at the surface can be achieved in a number of different ways, 
including the use of adhesion molecules. A review of literature revealed that a number of 
different molecules may be used to increase cell adhesion. These molecules include a 
variety of proteins and peptides. A list of possible cell adhesion molecules can be viewed 
in Appendix A: Summary of Cell Adhesion Molecules.  
 
With further research, it was concluded that fibronectin and RGD peptides were feasible 
for use as a cellular adhesion molecule when applied to fibrin microthreads 41, 42. As an 
ECM protein, fibronectin participates in a number of cellular processes including tissue 
repair, wound healing, and cell migration/adhesion. Additionally, RGD peptides have 
been investigated as a cellular adhesion molecule in a number of different scaffolding 
approaches. The outcome of such studies suggests that in low concentrations RGD 
peptides are actively able to stimulate mesenchymal stem cell attachment to a scaffold 42.  
 
2.7.3 Cell Seeding Techniques 
Another method to improve cellular attachment on fibrin microthreads is to establish a 
superior cell seeding technique, as compared to those currently used in Professor 
Gaudette’s lab. The initial step in adhering cells to a platform, is cell seeding. Cell 
seeding is fundamental in all tissue engineering applications that incorporate cells onto a 
platform prior to culture or implantation 43. Through the improvement of a cell seeding 
method, cell density can be increased. Advantageous features for any seeding technique 
include minimized cell injury, high seeding efficiency, reduced seeding time, and 
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reproducibility. Cells can be destroyed through adverse effects, such as apoptosis or cell 
lysing. In order for in vitro cell growth to take place within the scaffolds, the seeding 
technique must minimize these adverse effects 44. Additionally, the efficiency of the 
seeding technique influences the cell distribution and consequently affects the ability to 
achieve homogeneity in the cultured tissues. Efficiency is critical to cell seeding for 
multiple reasons. Any significant reduction in the total time required for cell seeding 
could also lead to substantial reductions in expense. Further, long seeding periods can 
result in adverse effects in which cells might expire or age beyond their useful state, 
which, in turn, affects the cells’ adhesive, proliferation, and differentiation processes 38.  
 
There are a myriad of methods for seeding cells. These methods can ultimately be 
divided into two types of seeding; static or dynamic. Static seeding is performed by 
depositing a concentrated cell suspension directly onto the platform. Currently, fibrin 
microthreads are seeded using several static methods, including the droplet and migration 
techniques. In droplet seeding, droplets of cell suspension are placed along the length of 
the microthreads. For migration seeding, microthreads are placed on polymer pedestals, 
allowing the cells to migrate off of the pedestal and onto the microthread. Dynamic 
seeding procedures involve stirring or agitation of cells in suspension together with the 
fibrin microthreads. Previously described devices developed for dynamic seeding take 
advantage of different, single driving forces such as filtrations 45, rotations 46, electric 
field 47, magnetic field 48, or vacuum 49. The use of a seeding device is often difficult 
since mechanical forces are usually involved in seeding procedures and can be 
responsible for shear-mediated membrane lysis or triggering of apoptotic pathways 50. 
However, studies have shown that the dynamic seeding methods render a more uniform 
cell distribution within scaffolds, obtaining larger cell yields when compared to static 
seeding 51.
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3.0 Project Approach 
 
3.1 Project Hypothesis 
3.1.1 Hypothesis #1  
Dynamic cell seeding will increase hMSC density on fibrin microthreads in a reduced 
time compared to static seeding. 
 
Rationale: Personal communication with Masters of Science candidate Megan Murphy 
demonstrated that current methods for seeding of cells onto fibrin microthreads are static 
seeding techniques. The current method of static seeding is droplet seeding.  In this 
method, the fibrin microthreads are adhered to a washer and a drop of cell suspension 
(500,000 cells/mL), is placed on the washer. Gravity allows for the cells to attach to the 
fibrin microthread. The limitation of the droplet method is that many of the cells do not 
attach to the fibrin microthread while gravity induces the cells to fall to the bottom of the 
culture plate. This method provides an attachment of 37±19 hMSCs/mm on a hydrated 
bundle of three fibrin microthreads for a 24 hour seeding duration. 
 
Studies have shown that the dynamic seeding methods render a more uniform cell 
distribution within scaffolds with larger cell yields when compared to static seeding 51, 52. 
Therefore, because of the inefficiencies of the current methods, an improved cell seeding 
technique should allow for increased cell density in a reduced time period. 
 
Specific Aim: Design a dynamic seeding method that increases cell density in a reduced 
time period as compared to static seeding.   
 
3.1.2 Hypothesis #2 
Physical surface alterations, namely bundling fibrin microthreads, will enhance the 
attachment of hMSCs on fibrin microthreads. 
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Rationale: Microgrooves have the ability to control the spatial organization of cells 
because the distribution and adhesion of cells are highly regulated 40. As demonstrated 
previously, cells align on bundles of microthreads longitudinally, and fill in the gaps and 
grooves between microthreads 5. Therefore, if bundled, fibrin microthreads may provide a 
topography that induces increased hMSC attachment. 
 
Specific Aim: Compare the number of hMSCs attached to individual fibrin microthreads 
and bundled fibrin microthreads with comparable diameters.  
 
3.1.2 Hypothesis #3 
The application of adhesion molecules, namely fibronectin, to the surface of fibrin 
microthreads will increase cellular affinity for the microthreads, and thereby improve cell 
density and attachment. 
 
Rationale: The interaction of cells with solid substrates is important for their attachment. 
Cells can attach, spread, and migrate on a variety of extracellular glycoproteins including 
fibronectin, laminin, vitronectin, and collagen. These interactions occur through specific 
cell surface receptors 53.  As an ECM protein, fibronectin participates in a number of 
cellular processes including tissue repair, wound healing, cellular migration, and cellular 
attachment 41. With its role in cell adhesion, many studies have been focused on using 
fibronectin as a means to increase cell attachment on synthetic scaffolds 42. Results from 
these studies suggests that fibronectin is able to induce significant motogenic activity in 
hMSCs 54. Therefore, the application of fibronectin onto the surface of fibrin 
microthreads could assist in the attachment and migration of cells. 
 
Specific Aim: To adsorb the adhesion molecule, fibronection, to the surface of fibrin 
microthreads to increase cell density.  
 
 - 14 - 
3.2 Project Assumptions 
To develop a manageable model of our design, several primary project assumptions were 
established: 
• The use of hMSCs in an infarcted area will produce advantageous results in 
myocardial regeneration 
• Fibrin is the best possible choice as a cellular platform for microthreads  
 
3.3 Project Goals 
As previously stated, the ultimate goal of the project was to develop a method to increase 
cell density on fibrin microthreads. To accomplish this task, we proposed the following 
specific aims: 
• Design and develop methods that will result in increased cellular attachment to 
fibrin microthreads 
o Enhance cell-seeding technique on fibrin microthreads 
 Design equipment that will support the developed cell-seeding 
technique 
o Explore bundling of fibrin microthreads as a technique to increase cell 
density on microthreads 
o Determine if utilizing fibronectin, as an adhesion molecule, will  increase 
cell density on microthreads 
• Develop a method to quantify cell density on microthreads 
 - 15 - 
4.0 Design  
4.1 Objective, Functions and Specifications 
Objectives 
Based on meetings with the clients and users of the final product, paired with a review of 
relevant literature, design objectives were produced for the device. These objectives were 
based on how the stakeholders (designers, clients, and users) ‘want’ the device to 
perform. An evaluation of these objectives and their relative importance to the 
stakeholders can be found in the pairwise comparison chart (Table 13 and Table 14) and 
objective tree (Figure 19) in Appendix B: Objectives. These objectives are categorized 
below: 
Cell density and cell quantity 
• Increase cell density from that received with the current static (droplet) seeding 
technique (37 hMSCs/mm in 24 hours) 
• Decrease the time to achieve increased density compared with current technique 
• Maximize cell quantity on microthreads 
• Control quantity of cells delivered 
Cell attachment 
• Strength of cell attachment; cells cannot be sheared off when being implanted 
• Number of cells attached 
Mechanical integrity 
• Maintain mechanical integrity of microthreads to allow them to function as 
sutures 
Cell alignment 
• Cell alignment in tissue 
• Cell alignment on microthreads 
Client convenience  
• Ease of use for client 
• Compatibility with other cell types or lineages 
• Easy and cheap to mass manufacture 
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The first category was the main objective, or goal, of this project. Prior to the selection of 
fibrin microthreads as a feasible scaffold for tissue regeneration, the cell density on the 
microthreads must be increased. To increase the density of the cells and maintain the 
viability of microthreads as a scaffold platform, the speed at which the increased density 
was attained must be maximized. Maximization of the speed of increased cell density 
minimizes the amount of time the cells can remodel the fibrin. Remodeling of the fibrin 
by the cells is detrimental because it decreases the mechanical integrity of the fibrin 
microthreads. Concomitant with increasing cell density and speed, it was necessary to 
control the quantity of cells delivered to the heart. By controlling the quantity of cells 
delivered on the microthreads, the process is made repeatable, and thereby marketable as 
a scaffold device.  
 
The second objective, although similar to the first, stipulates that, not only should the 
density be increased, but the cells that are on the microthreads need to adhere. It was 
central to increasing cell density that the cells attached to the microthreads.  The strength 
of cell attachment implied the ability to transport and manipulate the device without the 
microthreads detaching. The number of cells attached denotes that once the fibrin 
microthread has reached its maximum cell capacity, all of the cells are attached. 
 
Following cell density and attachment, maintaining the mechanical integrity of the 
microthreads was vital. The cells must be seeded rapidly, without detaching; otherwise 
the mechanical integrity of the system will be compromised. Therefore, the microthreads 
needed to be compiled into a cellular delivery device, where cells could be seeded 
densely onto the microthreads (prior to fibrin remodeling), so as to ensure no loss in 
mechanical integrity. For this compilation to occur, the microthreads must be transported 
without any additional loss of mechanical integrity. 
 
The third category related to the alignment of cells, both on the microthreads and in the 
tissue. This was a minor objective, because by bundling the microthreads, the cells are 
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inherently aligned on the microthreads. Yet, the alignment of the cells upon delivery to 
cardiac tissue may increase global heart function, due to increased scar compliance 27.  
 
These objectives would not be constructive unless the fifth objective was met. The final 
device must be easy to use by the client, and therefore easily deployed in the heart. The 
methods devised for increasing cell density and attachment must be feasible with the 
available technology and budget constraints. Additionally, ease of use to the client would 
enhance the project; if compatibility with other cell types and lineages was maintained, 
and the device was easy, cheap, and scalable for manufacturing. 
 
Functions 
While an objective is something that the device should accomplish, a function is 
something that the device must do. An elaborate listing of functions can be found in the 
morphological chart (Table 15) and function enumeration in Appendix C: Functions. 
The following list is a brief overview of what the functions that the microthread must do 
in order to accomplish our project goals and objectives. 
 
• Must be biocompatible  
• Maintain mechanical integrity of the microthread 
• Must be transportable 
• Prevent cell lysing and apoptosis 
• Produce limited by-products 
• Must be scaleable for implantation into animal and human tissues 
• Must be deliverable to the organ or tissue of interest 
• Increase cell density 
 
Although the design process begins with the production of the microthreads, it was first 
necessary to consider safety. If the system to increase density on the microthreads was 
successful, it would not be significant if it was not safe for patient use. Once the 
microthreads were made, they must be transportable. During the transportation process, 
they cannot break or tear, as they must be fully intact. Once the microthreads have been 
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transported to the hood, for cell seeding, they must be sterile for cell culture. With the 
cells on the microthreads, not only must the microthreads provide a hospitable 
environment for the cells to survive, but the mechanical integrity must be maintained. 
This is vitally important to the success of the project as fibrin is remodeled quickly.  
 
Constraints 
• Must be biocompatible 
o Must be composed of nontoxic material 
o Must have nontoxic degradation products 
• Must have adequate mechanical integrity and be delivered to the heart tissue 
• Must be cost effective for both producers and the consumers 
o Cannot cost more than our allotted budget 
• Must be finished by April 2008 
 
These constraints were devised to immediately filter out any design alternatives that were 
not feasible.  The device must be biocompatible as it will be inserted into the body; an 
immune response is not desirable. The device will be placed into the heart and therefore 
must have adequate mechanical integrity to be implanted in the heart. The costs must 
remain within the designated cost budget and also must be completed before the due date 
in April 2008.  
 
4.2 Specifications 
Following the clear definition of the project objectives, functions and constraints; design 
specifications were developed to detail the specific performance standards that the device 
must fulfill. These specifications were developed to help assess the efficacy of the device 
after the completion of experimental analysis. The overall specification for the number of 
hMSCs on fibrin microthreads that should be obtained are given in Table 1.  
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Specification Description 
Cell Density Increased cell quantity in a shortened 
seeding duration from that achieved with 
static seeding on individual microthreads 
(37 cells/mm in 24 hours). 
Table 1. Specifications. 
 
As defined by our initial project statement, the goal of this project was to increase cell 
density on fibrin microthreads. To apply the maximum number of cells per microthread, a 
confluent monolayer should be achieved. Calculations for obtaining this specification are 
located in Appendix D: Calculations for Specifications.  
 
To put this specification into better perspective, one must examine the amount of cells 
necessary to deliver to a region of infarction. Heart failure can occur when an infarct kills 
approximately 25% of the left ventricle, or 1 billion cardiomyocytes 7. To replace this 
many cells would take a large quantity of fibrin microthreads). Current technology cannot 
achieve the goal of complete regeneration, however substantial physiological benefit, or 
repair, can be derived from the engraftment of cells into the infarcted heart 55. It is 
important to note that the success of cell engraftment is not quantified in the majority of 
the human studies; thus the results are interpreted as a qualitative correlation of 
functional changes.  
 
Although extensive research has not been done involving hMSC engraftment in the 
human heart, studies have investigated engraftment rates in animal models. Research has 
indicated that noticeable improvement to cardiac function occurs when 230,000 or more 
hMSCs are engrafted into the rat heart 24,2. This implies that a minimum of 230,000 
hMSCs must be delivered to the heart, assuming a 100% engraftment rate. With our 
specification that there must be an individually confluent layer of 1,017 cells per one mm 
of length on a hydrated bundle of 10 fibrin microthreads. This suggests that we must have 
a minimum of 
cmmm
mm
cells
cells 6.22226
1017
000,230
==
of a hydrated bundle of 10 fibrin microthreads 
sutured into a rat heart.  
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Delivery 
method 
Number of 
cells delivered 
Percent 
Engrafted 
Total number of 
engrafted cells 
Animal 
model 
Collagen 
scaffold 24 
1 million 23% 230,000 Rat 
IC 
(intracoronary) 
infusion 3 
50 million 6% 3 million Porcine 
EC 
(endocardial) 
injection 3 
50 million 3% 1.5 million porcine 
IM injection 2 4 million 6-12% 240,000-480,000 Rat 
Table 2. Engraftment rates from previous animal studies.  
Note: This is not the exact number of viable cells delivered; as calculating the exact percentage of cells 
delivered is complicated by an unknown rate of hMSC proliferation and loss. 
 
4.3 Client Statement 
Therefore, based on the aforementioned objectives, functions, constraints, and 
specifications, the client statement was re-evaluated.  
 
4.3.1 Initial Client Statement 
Design a system to increase cell density on biological microthreads for use in adult stem 
cell-assisted cardiovascular regeneration. 
4.3.2 Revised Client Statement 
Design a system to increase cell density on biological microthreads for use in cellular 
assisted cardiovascular regeneration. These biological microthreads must be 
biocompatible, using natural biomaterials that do not elicit an adverse tissue response. 
Microthreads must be able to support human mesenchymal stem cells (hMSCs), which 
should assist in increasing global heart function in the infarcted heart. In order to allow 
for the regeneration of ischemic tissue, optimal cell density and cell quantity must be 
achieved. Based on literature references and preliminary data, a bundle of 10 fibrin 
microthreads, assuming individual confluency, must be able to support 370-1017 cells 
per millimeter.  This confluent monolayer of cells must be achieved in the shortest 
 - 21 - 
duration possible, as fibrin microthreads are rapidly remodeled by cells, typically within 
one week. In addition to maintaining the mechanical integrity of the fibrin microthreads 
via rapid seeding technique, the strength of cell attachment must be strong enough to 
withstand the shear of suturing through the heart. To make this an industrially applicable 
technique, the biological microthreads must be easily delivered using standard surgical 
techniques. 
 
4.4 Developing Design Alternatives 
This section analyzed the process followed to develop basic design concepts, create 
design alternatives, and select a final design. The initial stages of this process begun by 
identifying various means to fulfill the functions which then combined the means into 
design alternatives. The design alternatives were then critiqued based on their ability to 
fulfill our objectives and constraints. Finally, the most compatible design was selected.  
 
4.4.1 Morphological Chart and Evaluation Matrices 
The morphological chart, shown in Appendix C: Functions Table 15 lists all the 
functions along with the possible means to carry out each function that were produced via 
brainstorming (Appendix E: Design Alternatives). To form design alternatives, 
combinations of rational and feasible means were paired. The following list details a 
number of the possible alternatives: 
 
• Dynamic seeding (rotation seeding), cell adhesion molecule, bundled 
microthreads 
• Static seeding (droplet method), cell adhesion molecule  
• Dynamic seeding (rotation seeding), surface modification (microgrooves) 
• Static Seeding (droplet method), surface modification 
 
These alternatives were organized into a numerical evaluation matrix and weighted 
according to how well they fulfilled the constraints and objectives. A list of detailed 
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metrics can be seen in Appendix E: Design Alternatives. An evaluation matrix was 
compiled to evaluate each candidate design. An excerpt of this table can be seen in Table 
3. Each objective was broken down and defined on a scale of 0-2, with 0 being the least 
promising and 2 being the most promising in fulfilling the objective. For example, the 
objective ‘number of cells attached’ was given a score of 2 if the design had very high 
potential for increasing the number of cells attached to the fibrin microthread, and a score 
of 0 was given if the design would not feasibly increase the number of cells attached to 
the fibrin microthread. 
 
Objectives &  
Constraints  
 
Design 
 
Weight Design 1 Design 1 Design 1 Design 1 
Constraint 1 Y/N     
Objective 1 0.133     
Total Score      
Table 3. Sample evaluation matrix to evaluate design alternatives. 
 
The top row lists the design alternatives, and the left column lists the design objectives 
(O) and constraints (C). The second column shows the objective weights that were 
established earlier from the weighted objective tree. The designs were evaluated by 
scoring them against the metrics (0, 1, or 2) and then multiplying by its corresponding 
objective weight. Constraints were given a score of Y or N based on the designs ability to 
fulfill the constraint (Y: Yes) or inability to fulfill the constraint (N: No). The final score 
for the design was obtained by adding the weighted metric score for each objective. The 
top design candidates can be seen in Table 4. The full list of evaluated designs and 
total scores, along with a description of each design and justification of scoring, can be 
found in Appendix E: Design Alternatives. 
 
Design Alternatives Total Score 
Dynamic seeding (rotation seeding), cell adhesion molecule 1.33 
Static seeding (droplet method), cell adhesion molecule .701 
Dynamic seeding (rotation seeding), surface modification (microgrooves) .979 
Static Seeding (droplet method), surface modification .824 
Table 4. Evaluation of design alternatives. 
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After the basic methods to increase the attachment of hMSCs to fibrin microthreads were 
established, several candidate options for surface alterations, cell adhesion molecules, 
and cell seeding techniques were evaluated against the design objectives using another set 
of metrics. Detailed calculations for these metrics can be seen in Appendix E: Design 
Alternatives. Each objective was placed in a scale of 0-2, following the same process as 
listed above with 0 being the least favorable and 2 being the most favorable in fulfilling 
the objective. After these metrics were established, an evaluation matrix was made to 
evaluate each of the candidates under the three methods for increasing cell density. An 
example of this table can be seen in Table 5. Additionally, Table 6 provides the scores 
associated with each candidate for seeding technique, surface alterations, and surface 
adhesion molecules. 
 
Objectives 
 
Objective 1 Objective  2 Objective  3 Total 
Objective Weights 
 
.133    
Method 1 X (.133)    
Table 5. Sample evaluation matrix evaluating each of the candidate methods for increasing cell 
density. 
 
Candidate Methods to 
Increase Cell Density 
Subcategories Total Score 
Dynamic seeding technique 
 
1.67 
 Rotational seeding 1.67*1.44=2.40 
 Stirred seeding 1.67*0.68=1.14 
 Agitation 1.67*0.41=0.68 
Physical surface alteration  1.09 
 Bundling of microthreads 1.09*1.34=1.45 
 Patterned microgrooves on 
microthreads 
1.09*0.73=0.79 
 Electrospray onto microthreads 1.09*0.256=0.28 
Cell adhesion molecules  0.99 
 Fibronectin 0.99*1.34=1.32 
 RGD peptides 0.99*0.73=0.72 
 Collagen 0.99*0.71=.070 
 Laminin 0.99*0.46=0.45 
Table 6. Ranking of each candidate method to increase cell density on microthreads.
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Part II. Methods and Results 
5.0 Methodology 
This chapter encompasses the methods for producing and testing the selected materials 
and methods to increase cell attachment to the fibrin microthreads. The production of the 
microthreads, methods for seeding, and methods for quantifying the attachment of 
hMSCs to fibrin microthreads are discussed.  
 
5.1 Cell Culture 
A majority of the experiments conducted in correlation to the completion of this project 
required the use of cultured cells. Experiments were performed using passage 14-19 
hMSCs (Lonza, Allendale, NJ) cultured in Dulbecco’s modified Eagle’s Medium 
(DMEM; Mediatech, Herndon, VA) enhanced by 10% fetal bovine serum (FBS; 
Mediatech, Herndon, VA) and 1% penicillin streptomycin (Mediatech, Herndon, VA).  
 
To maintain sterility, all cell culture experiments were completed aseptically in a 
biological safety hood. An exact cell culture protocol can be viewed in Appendix F: Cell 
Culture Protocol.  Cells used in each experiment were incubated at 5% CO2 and 37°C 
in tissue culture treated flasks.  
 
5.2 Fibrin Microthread Production 
Fibrin microthreads were self-assembled from solutions of fibrinogen and thrombin using 
a coextrusion process employing a blending applicator tip (Micromedics, St. Paul, MN), 
which consisted of a dual bore (25 ½ gauge; BD, Franklin Lakes, NJ) needle attached to 
PE (polyethylene) tubing (BD, Franklin Lakes, NJ). Two diameters of PE tubing (ID 0.38 
mm / ID 0.58mm) were utilized to create different diameter microthreads. In this system, 
fibrinogen and thrombin solutions were warmed to 37°C and placed into separate 1 mL 
syringes (BD, Franklin Lakes, NJ). The fibrinogen solution was prepared fibrinogen from 
bovine plasma (Sigma, St. Louis, MO) that was dissolved in HEPES buffered saline 
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(HBS; 20 mM HEPES, 0.9% NaCl; Sigma, St. Louis, MO) at 70 mg/mL. The other 
solution was prepared thrombin from bovine plasma (Sigma, St. Louis, MO) that was 
stored frozen as a stock solution at a concentration of 40 U/mL in HBS and then was 
diluted from the stock to a final concentration of 6 U/mL in 40 mM CaCl2 solution. 
  
The blending applicators Luer lock to the two 1-ml syringes through individual bores. 
The individual bores, enabled the simultaneous extrusion of the contents of two separate 
syringes filled with fibrinogen and thrombin. With the aid of a syringe pump (Sage 
Instruments, Cambridge, MA), the two solutions were simultaneously extruded through 
the PE tubing at a pump speed of 0.125 ml/min into a bath of 10 mM HEPES, pH 7.4 
maintained at room temperature. After allowing the coextruded thick diameter fibers 
(coextruded with 0.58 mm PE tubing) to self-assemble for 15 minutes, microthreads were 
removed from the bath, air-dried under the tension of their own weight, and stored at 
room temperature until use. The thin-diameter fibers, which were coextruded with 0.38 
mm PE tubing, were allowed to self-assemble for 15 minutes and the microthreads were 
removed from the bath and bundled into groups of three, five, or ten microthreads when 
damp. The bundled microthreads were then air-dried under the tension of their own 
weight, and stored at room temperature until use. 
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Figure 1. Schematic drawing of coextrusion system for producing self-assembled fibrin microthreads.  
Image adapted from a schematic by Cornwell, 2007. 
 
To sterilize the fibrin microthreads, they were placed into a 1-well tissue culture plate 
(BD, Franklin Lakes, NJ). The microthreads were then rehydrated in sterile Dulbecco’s 
phosphate buffered saline (DPBS; Mediatech, Herndon, VA) for 15 minutes, sterilized 
with isopropyl alcohol (Sigma, St. Louis, MO) for 1 hour, and then rinsed three times in 
sterile DPBS for 15 minutes.   
 
5.3 Preliminary Experiments 
Initial experiments were conducted comparing the number of cells adhered to fibrin 
microthreads using dynamic versus static seeding techniques. Additionally, these 
preliminary experiments evaluated the number of cells adhered to bundles of three thin 
diameter (hydrated diameter: 140±56 µm) fibrin microthreads versus individual thick 
diameter (hydrated bundled diameter: 123±27 µm).  
 
5.3.1 Static Seeding: Droplet Method 
The current seeding technique developed to seed hMSCs onto fibrin microthreads is 
droplet seeding, which is a form of static seeding.  Static seeding using the droplet 
method follows the previously mentioned techniques for fibrin thread production. Once 
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sterilized, thick fibrin microthreads and bundles of three fibrin microthreads were cut to 
2.5 cm in length and were glued to 3.0 cm aluminum washers with sterile silicone 
adhesive (Silastic Silicone Type A; Dow Corning, Midland, MI). Concurrently, 
ThermanoxTM coverslips (Nalge Nunc International, Rochester, NY), which had been 
sterilized for 1 hour in isopropyl alcohol, were glued with the same silicone adhesive to 
the middle of each well of two 35 mm wells of a 6-well tissue culture plate (BD, Franklin 
Lakes, NJ) to serve as defined cell-seeding areas. The microthreads on washers were 
placed on top of the ThermanoxTM coverslip in the 35 mm well and the silicone adhesive 
sets for 24 hours. Following standard procedure for passaging, hMSCs were released 
from monolayer with trypsin, centrifuged, and re-suspended at a concentration of 500,000 
cells/mL in media (10% FBS and 1% Penicillin Streptomycin in DMEM).  Using a 1-mL 
syringe and a 27 ½ gauge needle, 100 µL of hMSC suspension were added to each well, 
over the microthreads and onto the ThermanoxTM coverslip (Figure 2).  The 6-well tissue 
culture plates were then placed into 37° C, 5% CO2 incubators.  At 24 hours, washers 
with microthreads were removed from the 35 mm wells and the microthreads were then 
stained with Hoechst dye (according to 5.4.2 Hoechst Nuclear Stain). The microthread 
bundles were then viewed on a glass slide under a fluorescent microscope.  Cell counts 
were taken, and attachment was assessed relative to the number of seeded cells per 
millimeter of fibrin microthread. Once the cells were stained and imaged with Hoechst 
dye, the microthreads were placed in 96 well plates (BD, Franklin Lakes, NJ) which 
contained 100 µl of media. One additional column of media was added as a control, as 
well as one column with media and sterilized microthreads without cells. 20 µl of MTS 
(Promega, Madison, WI) was added and allowed to sit for 4 hours and then the 
absorbance was read at 490 nm (according to 5.4.1 MTS Assay). 
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Figure 2. Schematic of droplet seeding. 
Image adapted from a schematic by J. Guyette. 
5.3.2 Dynamic Seeding: Rotational Method 
To improve the density of hMSCs attached to fibrin microthreads, as compared to the 
static (droplet) seeding technique, a new dynamic seeding technique was developed, 
utilizing a rotational seeding system.  Following fibrin microthread production and 
sterilization, the microthreads were threaded through 5cm of Silastic tubing (1.98 mm 
inner diameter (ID) x 3.18 mm outer diameter (OD); Dow Corning, Midland, MI) using a 
guide wire to pass the microthreads through the tubes. Following standard procedure for 
passaging, hMSCs were released from monolayer with trypsin, centrifuged, and re-
suspended at a concentration of 500,000 cells/mL in media (10% FBS and 1% Penicillin 
Streptomycin in DMEM). 1 µl of cell suspension was then added to Eppendorf tubing to 
facilitate the injection process. Each piece of Silastic tubing was then injected with 100 
µm of cell suspension (Figure 3) using a 1-ml syringe and a 27 ½ gauge needle. A 22 
gauge needle (BD, Franklin Lakes, NJ) was used to release the pressure when injecting 
the solution. The labeled tubes were then attached to a rotational seeding device (4 RPM; 
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Figure 4) within a incubator set at 5% CO2 and 37°C. The tubes were left to rotate for 24 
hours, removed from the rotational seeding device and then analyzed using the Hoechst 
nuclear stain and MTS viability assay.  
 
 
Figure 3. Cell suspension being injected into Silastic tubing. 
 
 
Figure 4. Rotational seeding device. 
 - 30 - 
5.4 Cell Quantification  
Two methods were initially used to quantify the number of cells present on fibrin 
microthreads. The MTS assay was used in preliminary experiments, however, due to the 
lack of sensitivity of the MTS, the primary technique used for cell quantification in 
succeeding experiments was individually counting cell nuclei after the application of 
Hoechst dye.  
 
5.4.1 MTS Assay  
The MTS assay is used to measure the number of live cells in culture. Mitochondria 
break down a tetrazolium compound to form a purple formazen dye. The concentration of 
this dye is measured and related directly to the cell’s metabolic activity.  
 
Following cell seeding, fibrin microthreads were placed in individual wells of a 96-well 
plate. 100 µl of media was placed on top of the microthreads, along with 20 µl of MTS 
solution. Concurrently, a 96-well plate was set up according to Table 7 to be used as a 
standard curve for obtaining cell quantities per fibrin microthread. The plates were then 
incubated for up to 4 hours and the absorbance was read at 490nm.  
 
Plate 
Well 
Concentration 
(cells/mL) 
Cells/well 
(0.1mL) 
To obtain (total 0.325mL; 0.1 mL in 
triplicate + 0.025mL left over) 
A 35,000 3,500 0 ml media + 0.325ml stock 
B 30,000 3,000 0.046ml media + 0.279ml stock 
C 25,000 2,500 0.093ml media + 0.232ml stock 
D 20,000 2,000 0.139ml media + 0.186ml stock 
E 15,000 1,500 0.186ml media + 0.139ml stock 
F 10,000 1,000 0.232ml media + 0.093ml stock 
G 5,000 500 0.279ml media + 0.046ml stock 
H 0 0 0.325ml media + 0ml stock 
Table 7. MTS standard curve for cell concentrations. 
5.4.2 Hoechst Nuclear Stain 
Another method to quantify the number of cells present on fibrin microthreads was to use 
a nuclear stain, such as Hoechst dye (Sigma, St. Louis, MO), and then view cells under 
an optical microscope. Hoechst dye fluorescently labels the cells by binding to DNA. 
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This florescent marker excites at 350 nm and emits blue light at 460 nm, An example can 
be seen in Figure 5.  
 
 
Figure 5. Hoechst stained hMSCs. 
 
The dye was used after experiments to determine the amount of cells adhered to the fibrin 
platform.  Before applying the dye, the microthreads were washed for 15 minutes in 
DPBS and then fixed for 15 minutes using 4% paraformaldehyde. Once the cells were 
fixed, the Hoechst dye was made in a working solution by diluting it 1:6000 in DPBS. 
The dye was then applied to the microthreads for 15 minutes, washed in DPBS for 15 
minutes. Finally, the microthreads were mounted to the glass slide with an aqueous 
mounting media.  
 
5.5 Experimental Methods 
Preliminary results indicated that dynamic seeding (rotational seeding) was a more 
effective seeding technique than static seeding (droplet seeding) and that bundling thin 
fibrin microthreads encouraged a larger number of cells to adhere than individual thick 
fibrin microthreads. Due to these results, the ensuing experiments were conducted using a 
rotational seeding technique and bundled fibrin microthreads with only one parameter 
 - 32 - 
altered in each experiment. The experiments conducted, following the preliminary 
results, were as follows: 
 
5.5.1 Varying the number of fibrin microthreads in each bundle 
Individual fibrin microthreads were extruded, using the technique previously described 
(5.2 Fibrin Production), with 0.38 mm ID PE tubing. Briefly, these individual fibrin 
microthreads were bundled into groups of 3, 5, or 10, sterilized, and then placed in sterile 
Silastic tubing (ID 1.98 mm x OD 3.18 mm). Cultured hMSCs were then injected into the 
Silastic tubing containing the bundled fibrin microthreads and rotationally seeded (5.3.2 
Dynamic Seeding: Rotational Method) for 24 hours. 
 
5.5.2 Varying the seeding duration 
Individual fibrin microthreads were extruded, using the technique previously described 
(5.2 Fibrin Production), with 0.38 mm ID PE tubing. Briefly, these individual fibrin 
microthreads were bundled into groups of 10, sterilized, and then placed in sterile Silastic 
tubing (ID 1.98 mm x OD 3.18 mm). Cultured hMSCs were then injected into the Silastic 
tubing containing the bundled fibrin microthreads and rotationally seeded (5.3.2 
Dynamics Seeding: Rotational Method) for 12 hours, 24 hours, or 48 hours. 
 
5.5.3 Varying the seeding tube diameter 
Individual fibrin microthreads were extruded, using the technique previously described 
(5.2 Fibrin Production), with 0.38 mm ID PE tubing. Briefly, these individual fibrin 
microthreads were bundled into groups of 10, sterilized, and then placed in sterile Silastic 
tubing (ID 1.98 mm x OD 3.18 mm or ID 0.51 mm x OD 0.94 mm). Cultured hMSCs 
were then injected into the Silastic tubing containing the bundled fibrin microthreads and 
rotationally seeded (5.3.2 Dynamics Seeding: Rotational Method) for 24 hours. 
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5.5.4 Passively adsorbing an adhesion protein (fibronectin) to the fibrin 
microthreads 
Individual fibrin microthreads were extruded, using the technique previously described 
(5.2 Fibrin Production), with 0.38 mm ID PE tubing. Briefly, these individual fibrin 
microthreads were bundled into groups of 10, sterilized, and then placed in sterile Silastic 
tubing (ID 1.98 mm x OD 3.18 mm). Then, the microthreads were washed with DPBS 
and 100µl of fibronectin (50 µg/ml) (Sigma, St. Louis, MO) was injected into the Silastic 
tubing and placed at 4°C to allow for passive adsorption into the fibrin microthread 
bundles. After 24 hours, the fibronectin was removed from the Silastic tubing. Cultured 
hMSCs were then injected into the Silastic tubing containing the bundled fibrin 
microthreads and rotationally seeded (5.3.2 Dynamics Seeding: Rotational Method) for 
24 hours. 
 
5.5.5 Proof of concept: delivering hMSCs to cardiac tissue via suturing 
In order to test the feasibility of our project, fibrin microthreads were sutured through the 
epicardium of a heart from a 200 lb pig. Bundles of ten fibrin microthreads were 
rotationally seeded for 24 hours in thin diameter tubing (Silastic tubing, ID 0.51 mm x 
OD 0.94 mm). The first group was control fibrin microthreads that were Hoechst dyed, 
immediately following seeding. The second group of fibrin microthreads were sutured 
into the epicardium of the pig heart and pulled out of the tissue and then Hoechst dyed. 
An additional group was sutured into the cardiac tissue and then cryosectioned and the 
slides were then H & E stained.  
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 6.0 Results 
6.1 Preliminary Results 
To obtain an increased density of hMSCs on fibrin microthreads, initial experiments were 
conducted to investigate the effect of seeding technique and the effects of surface 
alterations, on hMSC attachment to fibrin microthreads. The microthreads were either 
statically seeded, using the droplet method, or dynamically seeded, using a rotational 
seeding technique. Additionally, these microthreads were either individual thick diameter 
threads (average diameter: 123±27 µm) or bundles of three thin fibrin microthreads 
(average bundled diameter:  140±56 µm). There is no statistically significant difference 
in these diameters when compared using a two-tailed, unequal variance t-test (p=0.1596). 
 
The results of this preliminary experiment can be seen in Figure 6 and Table 8. Results 
were obtained by counting the Hoechst-stained hMSCs under a fluorescence microscope. 
Although use of the MTS assay was investigated as an analysis technique to quantify the 
number of cells per microthread, the MTS results were not considered valid, as the MTS 
did not appear to have enough resolution or sensitivity to acquire an accurate cell count, 
as can be seen in Appendix G: MTS Sensitivity and Results.  Therefore, using a two-
tailed unequal variance t-test, preliminary results of Hoechst-stained hMSCs indicated 
that the bundles of three dynamically seeded fibrin microthreads (295±115 cells/mm) 
were statistically significant (p=0.007) compared to the group with the next largest 
average cells per millimeter, which was dynamically seeded thick microthreads (57±40 
cells/ mm). The cells tended to clump into large groups along the length of the fibrin 
microthreads, and did not provide a confluent monolayer, which can be seen in Figure 7. 
Other experimental groups provided even lower cell counts with the thick microthreads 
statically seeded at 37±19 cells/ mm and thin bundles of three microthreads statically 
seeded at 40± 24 cells/ mm. 
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Figure 6. Improved hMSC attachment on 24 hour rotationally seeded bundles of three fibrin 
microthreads. 
 
Static seeding 
with thick 
fibrin 
microthreads 
Static seeding 
with bundles of 
3 thin fibrin 
microthreads 
Dynamic 
seeding with 
thick fibrin 
microthreads 
Dynamic seeding 
with bundles of 3 
thin fibrin 
microthreads 
Overall 
average 
(cells/mm) 37 40 57 295 
Standard 
error 
(cells/mm) 19 24 40 115 
Table 8. Seeding technique and microthread bundling average and standard error of the quantity of 
cells per millimeter of microthread. 
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a)      b) 
      
Figure 7. a) Bundle of microthreads dynamically seeded with groups of hMSCs along the length of 
the microthread. b) Statically seeded thick fibrin microthread with fewer attached hMSCs. 
 
6.2 Rotator Design 
Based on these results, a rotational seeding device was designed (Figure 8 and Figure 9).  
 
Figure 8. Schematic drawing of the rotational seeding device. 
 
 - 37 - 
 
Figure 9. CAD drawing of the rotational seeding device. 
 
6.3 Results 
Following the preliminary results, which indicated that dynamic (rotational) seeding 
resulted in improved hMSC attachment on fibrin microthreads, a rotational seeding 
device was designed (Figure 8 and Figure 9). This rotational seeding device was used for 
seeding the hMSCs onto the fibrin microthreads in the following experiments. 
Additionally, the following results only use bundled microthreads, after preliminary 
results indicated that bundles of three thin fibrin microthreads had increased hMSC 
attachment, as compared to an individual fibrin microthread of approximately equivalent 
diameter. 
 
6.3.1 Comparison of number of fibrin microthreads per bundle: groups of 3, 5 
and 10 
Bundles of 3, 5, and 10 thin fibrin microthreads (individually extruded with 0.38 mm ID 
PE tubing and then bundled) were rotationally seeded for 24 hours and then compared for 
increased cells per millimeter of fibrin microthread. Using a two-tailed unequal variance 
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t-test, results indicated that the bundles of ten fibrin microthreads (345±225 cells/mm) 
were not statistically significant (p=0.197) compared to the group with the next largest 
average cells per millimeter, which was bundles of 5 fibrin microthreads (103±71 
cells/mm). The bundle of three fibrin microthreads provided even lower cell counts 
(46±25 cells/mm). These results can be viewed below Figure 10 and Table 9. 
Additionally, a confluent monolayer of hMSCs was achieved on the fibrin microthread, 
as compared to preliminary results which showed clumps of cells along the length of the 
fibrin microthread. 
Effect of the number of threads per bundle on hMSC 
attachment
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Figure 10. Graph showing improved hMSC attachment on bundles of ten fibrin microthreads 
rotationally seeded for 24 hours. 
 
 
Bundles of 3 fibrin 
microthreads 
Bundles of 5 fibrin 
microthreads 
Bundles of 10 fibrin 
microthreads 
Overall average 
(cells/mm) 46 103 345 
Standard error 
(cells/mm) 25 71 225 
Table 9. Average and standard error, comparing the cells per millimeter of microthread for bundles 
of 3, 5, and 10 fibrin microthreads. 
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6.3.2 Comparison of seeding duration of fibrin microthreads: 12, 24, or 48 
hours 
Bundles of ten fibrin microthreads were rotationally seeded for 12 hours, 24 hours, or 48 
hours then compared for increased cells per millimeter of fibrin microthread. Using a 
two-tailed unequal variance t-test, results indicated that the bundles of ten fibrin 
microthreads (648±234 cells/ mm) were found to be significantly increased (p=0.0002) as 
compared to both the 12 hour seeding duration and the 48 hour seeding duration. A 
confluent monolayer of hMSCs was achieved along the length of the fibrin microthread 
as can be seen in Figure 11.   Bundles of ten fibrin microthreads rotationally seeded for 
12 hours had 233±117 cells/ mm and those seeded for 48 hours had 208±115 cells/ mm. 
For the bundles of ten fibrin microthreads seeded for 48 hours the media diffused or 
leaked out of the tubing that was holding the rotationally seeded fibrin microthread. The 
results of this experiment can be viewed below in Figure 12 and Table 10.  
 
 
Figure 11 . A confluent monolayer of hMSCs on a bundle of ten fibrin microthreads rotationally 
seeded for 24 hours. 
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Figure 12. Graph showing improved hMSC attachment on bundles of ten fibrin microthreads 
rotationally seeded for 24 hours. 
 
 12 hours 24 hours 48 hours 
Overall average 
(cells/mm) 233 648 208 
Standard error 
(cells/mm) 117 234 115 
Table 10. Average and standard error, comparing the number of cells permillimeter of fibrin 
microthread for rotational seeding durations of 12 hours, 24 hours and 48 hours. 
 
6.3.3 Comparison of seeding tube diameter: thin or thick Silastic tubing 
Bundles of ten fibrin microthreads were rotationally seeded for 24 hours in thin diameter 
tubing (Silastic tubing, ID 0.51 mm x OD 0.94 mm) or thick diameter tubing (Silastic 
tubing, ID 1.98 mm x OD 3.18 mm) with the same quantity of cells in each tube (50,000 
cells per tube; 10 µl of 5,000,000 cells/ml in the thin diameter tubing and 100 µl of 
500,000 cells/ml in the thick diameter tubing) and then compared for increased cells per 
millimeter of fibrin microthread. Thick diameter tubing had been used in all prior 
experiments. 
 
Using a two-tailed unequal variance t-test, results indicated that the bundles of ten fibrin 
microthreads in thick diameter tubing (515±245 cells/ mm) resulted in statistically 
significantly (p=0.003) more hMSCs per millimeter of microthread as compared to 
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bundles of ten fibrin microthreads in thin diameter tubing (96±41 cells/ mm). For the 
bundles of ten fibrin microthreads seeded for in thin diameter tubing, the media diffused 
or leaked out of the tubing that was holding the rotationally seeded fibrin microthreads. 
The results of this experiment can be viewed below in Figure 13 and Table 11.  
 
Figure 13. Graph showing no improvement of hMSC attachment on bundles of ten fibrin 
microthreads rotationally seeded for 24 hours in thin diameter tubing. 
  
  
Thin (Silastic tubing, ID 
0.51 mm x 0.94 mm) 
Thick (Silastic tubing, 
ID 1.98 mm x 3.18 mm) 
Overall average 
(cells/mm) 96 515 
Standard error 
(cells/mm) 41 245 
Table 11. Average and standard error, comparing the number of quantity of cells per millimeter of 
fibrin microthread for thin and thick diameter tubing. 
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6.3.4 Proof of concept: suturing rotationally seeded, hMSC covered fibrin 
microthreads into a pig heart 
Bundles of ten fibrin microthreads were rotationally seeded for 24 hours in Silastic tubing 
(ID 1.98 mm x OD 3.14 mm). The first group was control fibrin microthreads that were 
Hoechst dyed. The second group of fibrin microthreads were sutured into the epicardium 
of the pig heart and pulled out of the tissue and then Hoechst dyed. A cell seeded fibrin 
microthread sutured through the epicardium of a pig heart can be seen in Figure 14. 
Additionally, the fibrin microthread in the porcine cardiac tissue was cryosectioned and 
can be viewed in Figure 15. A comparison of the control threads and the threads sutured 
fully through the heart can be seen in Figure 16. After being sutured fully through the 
porcine cardiac tissue, hMSCs remained on the bundles of ten fibrin microthreads.  
 
 
Figure 14. A bundle of 10 fibrin microthreads, seeded for 24 hours with hMSCs has enough 
mechanical integrity (i.e. the hMSCs have not remodeled the fibrin) to be sutured into the 
epicardium of a pig heart without breaking. 
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Figure 15. Cryosectioned porcine cardiac tissue with a bundle of 10 fibrin microthreads, stained with 
H & E. 
 
a)      b) 
  
Figure 16. a) Bundle of microthreads dynamically seeded for 24 hours and stained with Hoechst dye 
(control). b) Bundle of microthreads dynamically seeded for 24 hours, sutured into the epicardium of 
a pig heart, pulled out, and stained with Hoechst dye. 
 
7.0 Analysis and Discussion 
7.1 Preliminary Results 
The preliminary results indicated that dynamic seeding, using a rotational method, 
resulted in improved hMSC attachment as compared to static seeding, using a droplet 
 - 44 - 
method. Additionally, it was found that bundles of three thin fibrin microthreads had 
improved attachment when compared to individual thick fibrin microthreads. The intent 
behind bundling the fibrin microthreads was to increase the available surface area for the 
hMSCs, while maintaining approximately the same diameter as the thick fibrin 
microthreads. The bundles of three thin fibrin microthreads had an average bundled 
diameter of 140±56 µm and the individual thick diameter threads had an average 
diameter of 123±27 µm. There was no statistically significant difference in these 
diameters when compared using a two-tailed, unequal variance t-test (p=0.1596). 
The main benefit of dynamic seeding over static seeding is that shorter time durations 
were required to seed the same quantity of hMSCs on the fibrin microthreads. 
Furthermore, bundling hMSCs allows for a larger quantity of hMSCs to be seeded, as 
compared to an individual fibrin microthread of equivalent diameter. The advantage of 
having a large quantity of hMSCs seeded in a shorter time duration is that the time for the 
hMSCs to remodel the fibrin microthread is minimized, thereby maintaining the fibrin 
microthread integrity. The integrity of the fibrin microthread is critical because the 
microthreads must be sutured into the heart without fracturing. Additionally, a shorter 
seeding duration is clinically advantageous in that the microthreads could be potentially 
seeded immediately before a surgery.  
 
An additional benefit of rotationally seeding hMSCs in Silastic tubing is that a longer 
section of fibrin microthread can be seeded. A 100 µl droplet of cell suspension spans 1-2 
cm of the microthread in the droplet technique; since the fibrin microthread is placed in 
Silastic tubing for the rotational technique, 100 µl of the cell suspension is spans along 3-
4 cm of the microthread. 
 
7.1.1 Rotator design 
Based on initial results a rotational seeding device (Figure 8 and Figure 9) was 
constructed. This device was specifically designed to rotate at a slow speed (4 RPM), as 
previous investigations of dynamic seeding techniques have found that the use of a 
seeding device is difficult since mechanical forces can be responsible for shear-mediated 
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membrane lysis or triggering of apoptotic pathways 50,56. Additionally, a special arm was 
created to secure the Silastic tubing for rotation. This special arm consisted of a rubber 
piece and a plexiglass piece. The Silastic tubing was placed vertically between the rubber 
and plexiglass and secured with screws, so that the tubing was secure during rotation. The 
entire device was compact enough to fit into an incubator   
 
7.2 Results 
After receiving the preliminary results, subsequent experiments were conducted with a 
rotational seeding technique and bundles of thin fibrin microthreads. Experimental 
variables were analyzed independently, to investigate further methods for increasing 
hMSC attachment on fibrin microthreads.  
 
Fibrin microthreads were bundled into groups of 3, 5, and 10 and the attachment of  
hMSCs per millimeter of microthread was compared. The highest average number of 
hMSCs per millimeter was achieved by the bundles of 10 fibrin microthreads. The result 
was not statistically significant, however, bundles of 10 fibrin microthreads were selected 
for use in future experiments. A bundle of 10 fibrin microthreads (average bundled 
diameter: 0.36 mm) was similar to the size of sutures typically used in the heart (synthetic 
5-0 suture, diameter: 0.15 mm). Additionally, 10 bundled fibrin microthreads were 
stronger than bundles of 3 or 5 fibrin microthreads, making them more capable to 
withstand the mechanical forces when suturing into the heart. 
 
Following the selection of bundles of ten fibrin microthreads, the seeding duration was 
evaluated. It was found that seeding for 24 hours was optimum. At 12 hours of rotational 
seeding, the hMSCs were not as densely seeded on the fibrin microthreads as they were 
after 24 hours. After 48 hours of rotational seeding the media had either leaked or 
diffused out of the Silastic tubing, leaving the threads dry. Therefore there were fewer 
hMSCs attached to the fibrin microthreads after 48 hours, as compared to 24 hours. 
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In order to further increase the density of hMSCs on the fibrin microthreads, smaller 
diameter tubing was used for rotational seeding. This was done with the intent that 
condensing the hMSCs around the microthreads would increase the cell attachment, and 
could be potentially used as a protective sheath when suturing the microthreads. 
However, there was a statistically significant decrease in cell density when 0.51 mm ID 
Silastic tubing was used as compared to the 1.98 mm ID Silastic tubing, which had been 
used in the previous experiments. The decrease in cell density could have been caused by 
inadequate cell concentration (i.e. the cell concentration was too high for the smaller 
diameter Silastic tubing) or by media evaporation from the tubing.  
 
The final method investigated was the addition of an adhesion protein to the fibrin 
microthread. Fibronectin was utilized as an alternative method to increase surface 
adhesion, however after being passively adsorbed for 24 hours at a concentration of 50 
ug/ml, fibronectin did not enhance the quantity of cells on the fibrin microthreads. This 
could be for several reasons, including, but not limited to, the following: 
 
• The fibronectin may have preferentially adsorbed to the tubing and not to the 
fibrin microthreads  
• The fibronectin may have desorbed from the fibrin microthread during seeding 
 
It is unlikely that the hMSCs did not adhere to the fibronectin, as previous studies 
indicate that hMSCs have increased attachment on fibronectin, as compared to an 
uncoated surface or to other adhesion proteins 41. Therefore, the method of applying 
adhesion molecules to the fibrin microthreads needs further investigation to be 
formulated into an effective technique. 
 
Following the selection of bundles of ten fibrin microthreads rotationally seeded for 24 
hours in 1.98 mm ID Silastic tubing, the microthreads were evaluated for their ability to 
be sutured into cardiac tissue. It was shown that, overall, there were fewer cells on the 
fibrin microthreads after they were sutured through the heart. However, these images 
show proof of concept that hMSC-seeded fibrin microthreads can be utilized for cellular 
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delivery to cardiac tissue and that the hMSCs are not sheared off upon suture entry into 
the tissue. Due to the loss in the quantity of cells per millimeter of microthread which can 
be seen qualitatively in Figure 16, therefore in the future it is proposed that a protective 
encapsulating sheath be used for the cell seeding and suturing the microthread into the 
heart, as seen below in Figure 17 and Figure 18. 
a) b)  
c)  
 
Figure 17. Proposed mechanism for cellular delivery using fibrin microthreads. a) Seeding the 
microthreads in tubing. b)  Using the tubing as a protective cellular delivery sheath. c) Removing the 
sheath; leaving the cell seeded fibrin microthread in the heart. 
Image courtesy of J. Guyette. 
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Figure 18. Comparison of a 5-0 suture that is typically used in cardiac applications, a bundle of fibrin 
microthreads, a bundle of fibrin microthreads in the proposed protective sheath (also to be used as 
the bioreactor), and the current bioreactor. 
 
Based on the specifications found in Table 1, the maximum number of hMSCs that could 
conceivably be attached to the fibrin microthreads is between 370-1017 hMSCs per 
millimeter of a bundle of 10 microthreads. The lower specification value, 370 hMSCs per 
millimeter, is achieved when it is assumed that the bundle of 10 microthreads is 
approximately a cylinder (average diameter: 363 µm) and that individual, large diameter 
cylinder is then seeded. The higher specification value, 1017 hMSCs per millimeter, is 
achieved when you assume that individual microthreads (average diameter: 99.7 µm) are 
cylindrical in shape and are seeded with a confluent monolayer and then bundled. 
 
The average of all experiments conducted with bundles of ten fibrin microthreads 
dynamically seeded for 24 hours in 1.98 mm ID Silastic tubing, resulted in 
648±234cells/mm. This result falls within the design specifications found in Table 1 and 
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indicates that a nearly confluent monolayer of hMSCs on bundles of ten fibrin 
microthreads has been achieved.  
 
The specification upper specification limit of 1017 hMSCs per millimeter was not 
achieved because the individual fibrin microthreads were not seeded with hMSCs and 
then bundled. Instead, ten fibrin microthreads were bundled and then seeded with 
hMSCs. It can be seen in Figure 15 that microgrooves are present due to bundling the 
fibrin microthreads; however ten individual microthreads cannot be seen. It may be that 
when the fibrin microthreads are being seeded with hMSCs in media for 24 hours they 
begin to form one cylindrical thread. The partially microgrooved surface observed in 
Figure 15 validates that the number of cells achieved per millimeter (648 cells/mm) falls 
in a middle range within the specifications for a confluent monolayer (370-1017 
cells/mm). It should be noted that it is possible that bundling the microthreads may 
harbor more cells than can be achieved by a confluent monolayer. Additionally, the 
results revealed that more than one layer of cells were attached to the microthread. 
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8.0 Conclusions 
The following conclusions summarize our efforts towards creating a deliverable product 
in the field of cardiovascular regeneration. 
 
The use of fibrin microthreads as a method to deliver hMSCs is an innovative approach 
in regenerative medicine which has not been explored until recently. The current standard 
in seeding hMSCs onto the fibrin microthreads utilizes a static method in which cell 
suspension is dropped onto a microthread suspended across a stainless steel washer. 
Although this technique is able to attain a considerable amount of cells on the 
microthreads, the process requires an extensive period of time (up to 5 days to achieve 
maximal cell density), over which the microthread begins to degrade. The first step in 
improving this process was to test a new seeding process.  
 
Based on our results, we concluded that dynamic seeding provides a better method of 
attaching the hMSCs to the microthreads. In line with our original hypotheses, 
preliminary results indicated that dynamically seeding hMSCs onto fibrin microthreads 
provided a superior method of hMSC attachment than static seeding. In conjunction with 
the analysis of dynamic seeding, the effect of surface alterations, achieved via bundling 
the microthreads, was investigated. Once again, preliminary results suggested that 
bundling microthreads increased cell density. Each of these experiments was performed 
in a 24 hour time period, allowing the threads to maintain mechanical integrity. Upon 
analysis of results, it was concluded that bundled microthreads dynamically seeded for 24 
hours were able to increase cell density as compared to static seeding, seen in Figure 7. 
The duration of time at which the microthreads were rotated was also varied; however, 
microthreads rotated for 24 hours significantly increased cell attachment to the 
microthreads as depicted in Figure 11. Other parameters, such as tubing diameter and the 
effect of cell adhesion molecules on cell density were explored, resulting in low cell 
counts and therefore were not used in this project.  
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In conclusion, by dynamically rotating bundled microthreads for 24 hours, an average 
cell count of 648 cells/mm of microthread was achieved. This significant number 
suggests that despite their small size, enough cells can be delivered to the tissue of 
interest to provide a hospitable environment for regeneration. Results of this study 
suggest that the 648 cells/mm of bundled microthreads that have been rotationally seeded 
can be delivered to a rat heart in approximately 22.6 cm of microthreads assuming 100% 
engraftment. Although future testing is required, fibrin microthreads are a exciting and 
novel method for cardiac tissue regeneration.  
 
9.0 Future Recommendations 
Although the work that was completed in this project produced significant results, there 
are a number of additional pathways that can be explored to elicit even greater results that 
may ultimately lead to clinical trials for the treatment of MI.  
 
When beginning this project, the brainstorming process cultivated a number of ideas for 
use in increasing cell density on fibrin threads. These ideas included the use of cell 
adhesion molecules, directly coextruding hMSCs into the fibrin microthreads, and 
superficial surface alterations. Cell adhesion molecules have been used in previous 
research as a method to increase cell attachment to fibrin scaffolds. A number of cell 
adhesion molecules had been explored for such applications, including fibronectin, 
victronectin, and RGD peptides. Although preliminary testing was completed by 
passively adsorbing fibronectin on the microthreads, results were discouraging, as fewer 
hMSCs were attached to the microthreads with passively adsorbed fibronectin. However, 
use of a different cell adhesion molecule, such as vitronectin or RGD peptides may 
produce better results 
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A further idea to increase the quantity of hMSCs attached to fibrin 
microthreads is to coextrude the hMSCs within the fibrin microthreads. As 
outlined in  
5.2 Fibrin Microthread Production, fibrin microthreads are produced through the 
coextrusion of fibrinogen and thrombin with the aid of a syringe. This is a non-sterile 
process and thus requires further sterilization of the microthreads before they are threaded 
through the Silastic tubing. While coextrudeding the hMSCs when producing the 
microthreads is an attractive technique for a number of reasons, there are a number of 
inherent limitations with such a process. Limitations include creating a method to 
coextrude the hMSCs and fibrin in a sterile manner. This would require the purchase of 
additional equipment, including the possible purchase of a syringe pump.  
 
Another area that requires advancement for future research is the method of quantifying 
the number of cells per millimeter of microthread. When quantifying the number of cells 
on microthreads, the cells were counted by hand with the aid of the computer program 
Image J. This is a subjective technique that can be improved. The use of an assay such as 
MTS and Alamar Blue was explored, with disappointing results, as can be seen in 
Appendix G: MTS Sensitivity and Results. Results of such assay suggested that a more 
sensitive assay, or a different method altogether was necessary.  
 
In addition, although Hoechst dye was used to quantify the number of cells on the 
microthread, this method does not provide information about cell viability. Therefore, in 
the future, groups should explore the use of a live/dead assay to confirm that the cells 
being delivered to the tissue of interest are live, fully functional cells. Furthermore, a 
proliferation assay can also be used to determine whether the cells continue to divide, 
grow, and expand within the tissue. A cell-cycle marker such as Ki-67 may be a useful in 
determining such a parameter. Furthermore, the viability and differentiation of the 
hMSCs needs to be characterized before implantation in clinical trials.  
 
Within the methods touched upon in this project, there are a number of improvements 
that can be made including the possibility of a different dynamic seeding technique, 
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smaller diameter tubing, varied cell concentrations, and different cell types. As compared 
to static seeding, the use of the dynamic rotational method proved to be a successful 
method in this project, proving feasibility in increasing hMSC density on microthreads. 
However, other methods of dynamic seeding, other than the rotational technique 
employed in this study, may be used to further increase cell density and attachment. 
Additionally, different diameter tubes may be used in such applications. In particular, the 
use of smaller diameter tubing (<0.51mm ID) would be especially important because 
such tubing may be used in suturing the microthreads into the tissue of interest, acting as 
a mode of protection (of both cells and microthread) during the suturing process. The 
tubing used in this project (1.98mm ID Silastic tubing) was too large to be sutured into 
the heart. However, with smaller diameter tubing, the microthreads may be kept in the 
tube with the cell suspension, removing the tubing only after suturing is complete. This is 
advantageous for a number of reasons, including protection of the microthread. Also, it 
eliminates having to remove the thread from the tubing before suturing, which may shear 
cells off of the microthreads. However, there are limitations to such a process. This 
particular avenue was explored; resulting in low cell counts.  
 
Finally, upon optimization of hMSC density on or within fibrin microthreads, it is 
recommended that in vivo tests be conducted. These trials should investigate the effects 
of hMSCs delivered to the heart on fibrin microthreads, specifically the efficiency and 
localization of cell engraftment within the heart. Different avenues should be observed, 
including, but not limited to, engraftment rate of hMSCs in cardiac tissue, differentiation 
of hMSCs, and improvements in global heart function. 
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Appendix A: Summary of Cell Adhesion Molecules 
Substance What is it? Experimental Results 
Fibronectin Exists in two forms: 
• Insoluble glycoprotein dimer 
(ECM) 
• Soluble disulphide linked 
dimer (Plasma) 37 
Involved in many cellular processes: 
• Tissue repair 
• Wound healing 
• Cell migration and/or 
adhesion 
 
Has shown most potential 
as a cellular adhesion 
molecule 41; feasible for use 
in project  
RGD peptides • Tripeptide found in 
extracellular matrix proteins 
• Interact with integrin  receptor 
sites to initiate cell signaling 
• Modulator of cell adhesion 
 
RGD peptides stimulate 
MSC attachment and 
spreading 42; used in low 
concentrations; used in 
place of fibronectin; 
feasible for use in project 
Collagen • Collagen molecules form a 
wide range of structures 
within the human body 46 
• Fibrous tissue found in most 
connective tissues 
Promotes cell adhesion 57; 
not favorable for use as a 
microthread for hMSC 
applications 58 
Vitronectin • Abundant plasma protein  
• Regulates coagulation, 
fibrinolysis, complement 
activation, and cell adhesion 59 
Promotes cell adhesion 59; 
not favorable for use as a 
microthread for hMSC 
applications 58 
Laminin • Glycoprotein with 3 peptide 
chains 
• Varied functions: 
• Cell adhesion 
• Cell growth and                   
differentiation 
• Cell migration 
Mixed results obtained in 
scientific research 60 ; lack 
of reproducible results  
Table 12. Summary of cell adhesion molecules.
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 Appendix B: Objectives 
 
Objectives (O): 
O1 - Cell alignment in tissue 
O2 - Cell alignment on biological microthreads 
O3 - Increase cell density 
O4 - Increase speed of ‘more density’ 
O5 - Strength of cell attachment 
O6 - Number of cells attached 
O7 - Maximize cell quantity on biological microthreads 
O8 - Control quantity of cells delivered 
O9 - Promote proliferation of seeded cells 
O10 - Maintain mechanical integrity of biological microthreads 
O11 - Ease of use for client 
O12 - Compatibility with other cell types or lineages 
O13 - Easy and cheap to mass manufacture 
 
Objectives 
↓   → 
O1 O2 O3 O4 O5 O6 O7 O8 O9 O10 O11 O12 O13 Total 
O1 X 0 0 0 0 0 0 ½  0 0 1 1 1 3.5 
O2 1 X 0 1 0 0 0 1 ½  0 1 1 1 6.5 
O3 1 1 X ½  0 ½  1 1 ½  1 1 1 1 9.5 
O4 1 0 ½  X 0 1 ½  1 ½  1 1 1 1 8.5 
O5 1 1 1 1 X 1 ½  1 1 1 1 1 1 11.5 
O6 1 1 ½  0 0 X 1 1 ½  1 1 1 1 9 
O7 1 1 0 ½  ½  0 X 1 ½  1 1 1 1 8.5 
O8 ½  0 0 0 0 0 0 X 0 0 1 1 1 3.5 
O9 1 ½ ½  ½  0 ½  ½  1 X 1 1 1 1 8.5 
O10 1 1 0 0 0 0 0 1 0 X 1 1 1 6 
O11 0 0 0 0 0 0 0 0 0 0 X 1 1 2 
O12 0 0 0 0 0 0 0 0 0 0 0 X 1 1 
O13 0 0 0 0 0 0 0 0 0 0 0 0 X 0 
Table 13. Global, or overall, project objective pairwise comparison chart. 
 
Global Principal Objectives 
1. Increase cell density 
2.  Maintain mechanical integrity of biological microthreads
60 
 
Individual Principal Objectives 
 
• G. Gaudette 
1. Maintain mechanical integrity of biological microthreads 
2. Increase cell density 
3. Maximize cell quantity on biological microthreads/control quantity of 
cells delivered 
• M. Rolle 
1. Number of cells attached 
2. Maximize cell quantity on biological microthreads/increase speed of 
‘more density’ 
3. Increase cell density 
• M. Murphy 
1. Maintain mechanical integrity of biological microthreads 
2. Control quantity of cells delivered/strength of cell attachment 
• MQP 
1. Strength of cell attachment 
2. Increase cell density 
3. Number of cells attached 
 
Objective 
G. 
Gaudette 
M. 
Rolle 
M. 
Murphy MQP 
Averaged 
Total Weighted Objective  
Cell alignment in tissue 0.5 1.5 0 3.5 1.4 1.4 + 1= 2.4/78.1= .0307 
Cell alignment on biological 
microthreads 1.5 0 3.5 6.5 2.9 2.9 +1= 3.9/78.1= .0499 
Increase cell density 11 10 7 9.5 9.4 9.4 +1= 10.4/78.1= .133 
Increase speed of ‘more 
density’ 5 10.5 5.5 8.5 7.4 7.4 +1= 8.4/78.1= .108 
Strength of cell attachment 7 4.5 9.5 11.5 8.1 8.1 +1= 9.1/78.1= .117 
Number of cells Attached 8 11 6.5 9 8.6 8.6 +1= 9.6/78.1= .123 
Maximize cell quantity on 
biological microthreads 9 10.5 6.5 8.5 8.6 8.6 +1= 9.6/78.1= .123 
Control quantity of cells 
delivered 9 7 9.5 3.5 7.3 7.3 +1= 8.3/78.1= .106 
Promote proliferation of the 
seeded cells 6 2 3.5 8.5 5.0 5.0 +1= 6.0/78.1= .0768 
Maintain mechanical integrity 
of biological microthreads 12 7.5 10 6 8.9 8.9 +1= 9.9/78.1= .127 
Ease of use for client 5 4.5 8.5 2 5.0 5.0 +1= 6.0/78.1= .0768 
Compatibility  with other cell 
types or lineages 3 4.5 2 1 2.6 2.6 +1= 3.6/78.1= .0461 
Easy and cheap to mass 
manufacture 1 4.5 6 0 2.9 
2.9 +1= 3.9/78.1= .0499 
 
   Sum 78.1 1 
Table 14. Averages from all stakeholder's pairwise comparison charts 
 
61 
 
Figure 19. Objective tree.
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Appendix C: Functions 
 
FUNCTION POSSIBLE MEANS 
Prevent cell lysing and 
apoptosis 
Maintain nutrient 
rich environment 
around biological 
microthreads  
Maintain platform 
as amicable 
cellular 
environment  
Precondition 
cells to harsh 
ischemic 
environments  
Biological 
scaffold 
Biocompatible Use of patients own 
stem cells to 
minimize immune 
response  
Limited 
inflammatory 
response 
Non-toxic 
materials  
 
Limited Byproducts Avoid use of 
harmful solvents 
Limit degradation 
of cell platform 
Avoid necrosis 
prior to 
implantation 
 
Cell platform needs to 
maintain mechanical integrity 
(need to be able to be 
transferred from cell culture 
to delivery to the heart) 
Increase speed of 
cell migration via 
adhesion molecules  
Improve cell 
seeding technique 
Limit fibrin 
degradation 
through 
inhibitors 
 
Need to be transportable Develop 
transportation 
device 
Possible use of 
aseptic  cell culture 
dish 
Float biological 
microthreads in 
serum  
 
Need a sterile environment Aseptic cell culture 
techniques 
Use of biological 
safety hood 
Use of 
disinfectant 
 
Produce mass amount of 
biological microthreads 
Optimize biological 
microthread 
extrusion technique 
Hand extrude 
biological 
microthreads 
  
Must be deliverable to the 
organ or tissue of interest 
Through sutures Scaffolds Direct injection  
Increase Cell Density Bundling of 
biological 
microthreads  
Inhibit fibrin 
degradation 
Optimize cell 
seeding 
technique  
Cell 
adhesion 
molecules 
Table 15. Morphological chart. 
 
 
Function Enumeration 
 
o Biological microthread Creation 
o Maintain mechanical integrity (must produce one continuous biological 
microthread when drawing through solution) 
o Must provide hospitable environment for hMSCs 
o Must be scaleable (ability to produce mass quantity of biological 
microthreads) 
o Biological microthread Transportation to Incubation 
o Maintain mechanical integrity (cannot break or tear during transport) 
o Must provide a sterile environment 
o Cell Seeding 
o Must attach/adhere cells 
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o Must have a sterile environment for seeding 
o Prevent cell lysing and apoptosis during seeding 
o Cell Culture 
o Must maintain mechanical integrity (so that cells do not entirely remodel 
the biological microthreads) 
o Cells must proliferate while in cell culture 
o Cell culture must provide a sterile environment 
o Must limit deleterious byproducts 
o Prevent cell lysing and apoptosis 
o Biological microthread and Cell Transportation to Experimental Analysis 
o Maintain mechanical integrity (biological microthreads cannot break or 
tear during transport) 
o Must have sterile transportation vehicle 
o Experimental Analysis 
o Must have a sterile environment for experiments 
o Must limit deleterious byproducts 
o Prevent cell lysing and apoptosis 
o Biological microthread and Cell Transportation 
o Maintain mechanical integrity 
o Maintain sterile environment 
o Biological microthread and Cell Implantation 
o Must provide cells to area of interest 
o Must be adaptable for inimally invasive for implantation 
o Must maintain cell viability upon implantation (prevent cell lysing and 
apoptosis) 
 
o ***Design Safety 
o Biocompatibility must be maintained 
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Appendix D: Calculations for Specifications 
 
 
Figure 20. 10X image of hMSCs stained with Phalloidin (binds to filamentous actin and is green in 
the image) and Hoechst dye (binds to the nucleus and is blue in the image).   
Image courtesy of M. Murphy. 
 
 
Based off of Figure 20, the average cell area of a hMSC is 3079.23 µm2. Data for these 
area measurements can be found in Table 16. Additionally, Table 17, Table 18, and Table 
19 contain diameter measurements of hydrated bundles of 3, 5, and 10 fibrin 
microthreads. The average diameters of hydrated bundle of 3, 5, and 10 fibrin 
microthreads is 140 µm, 218 µm, and 363 µm, respectively. 
 
 
Figure 21. Cryosectioned porcine cardiac tissue with a hydrated bundle of 10 fibrin microthreads. 
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Method 1 for obtaining the number of cells per area of microthread of a confluent cell 
monolayer 
Assuming that a hydrated bundle of 10 fibrin microthreads is approximately a cylinder, 
the surface area of 1 mm of this bundle is: 
 
261014.11000
2
36322 mmmhrCylinderaofAreaSurface µµµpipi ⋅=⋅⋅⋅=⋅⋅⋅= of 
surface area for 1 mm (1000 µm) of a hydrated bundle of 10 fibrin microthreads 
One millimeter of a hydrated bundle of 10 fibrin microthreads can hold a confluent 
monolayer of: 
cells
cell
m
m 370
23.3079
1014.1
2
26
=
⋅
µ
µ
 
Method 2 for obtaining the number of cells per area of microthread of a confluent cell 
monolayer 
Number of threads versus average diameter
y = 25.587x + 74.116
R2 = 0.978
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Figure 22. Average hydrated diameter for bundles of fibrin microthreads versus the number of 
threads in the bundle. 
 
Based off of Figure 22, it can be extrapolated that one individual fibrin microthread has a 
diameter of 0.99703 mm. If the threads were individually seeded and then combined into 
a bundle of 10 fibrin microthreads a larger number of cells could be seeded, due to the 
increased surface area. Assuming that 1 hydrated fibrin microthreads is approximately a 
cylinder, the surface area of 1 mm of fibrin microthread is: 
251026.61000703.9922 mmmhrCylinderaofAreaSurface µµµpipi ⋅=⋅⋅⋅=⋅⋅⋅=
of surface area for one hydrated  fibrin microthread that is 1mm in length 
One millimeter of one hydrated fibrin microthread can hold a confluent monolayer of: 
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cells
cell
mm
m 7.101
23.3079
1013.3
2
25
=
⋅ µ
 
Therefore, if one millimeter of 10 of these individually seeded hydrated fibrin 
microthreads were bundled into a group, there would be: 
10 fibrin microthreads cells
mm
cells 10177.101 2 =⋅  
Based on these calculations, a confluent monolayer, one millimeter in length, of cells on 
a hydrated bundle of 10 fibrin microthreads can hold between 370 cells (when bundled 
and then seeded) and 1017 cells (when individually seeded and then bundled). 
 
Raw Data for hMSC Area and Fibrin Microthread Bundled Diameter 
 
Number of 
hMSCs counted 
Cell 
area 
(um2) 
1 3212.37 
2 2578.91 
3 2787.90 
4 2448.55 
5 2518.21 
6 1751.65 
7 7165.57 
8 1541.22 
9 2747.72 
10 2393.34 
11 2578.07 
12 2916.81 
13 3895.83 
14 1184.53 
15 1975.66 
16 1979.20 
17 2652.91 
18 7385.25 
19 6158.95 
19 2052.98 
21 3728.71 
22 3668.92 
23 2752.05 
24 1826.34 
Average 3079.23 
Standard 
Deviation 1630.44 
Table 16. Average hMSC area, based on Figure 20. 
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The diameters given are averages, based on measuring the diameter in three locations 
along the length of the thread for each Experiment Image. 
 
Experiment Image 
Diameter 
(µm) 
1-19-08_Rotated Bundles of 10_Thread 1 Image 1_Hoechst_10X_370.8ms 236 
1-19-07_Thread 2_Image 1_Bundled 10 Rotated_Hoechst dye_10X_250.9ms:Blue 227 
1-19-08_Rotated Bundles of 10_Thread 2 Image 1_Hoechst_10X_370.8ms 298 
2-1-08_Rotated Bundle of 10_Thread 1 Image 1_Hoechst_10X_196.6ms.tif 320 
2-1-08_Rotated Bundle of 10_Thread 1 Image 2_Hoechst_10X_50.4ms.tif 291 
2-1-08_Rotated Bundle of 10_Thread 1 Image 3_Hoechst_10X_50.4ms.tif 354 
2-1-08_Rotated Bundle of 10_Thread 1 Image 4_Hoechst_10X_50.4ms 363 
2-1-08_Rotated Bundle of 10_Thread 2 Image 1_Hoechst_10X_50.4ms.tif 339 
2-1-08_Rotated Bundle of 10_Thread 2 Image 2_Hoechst_10X_50.4ms.tif 399 
2-8-08_Rotated Bundle @ 12hr_Thread 1 Image 1_Hoechst_10X_127.0ms 297 
2-8-08_Rotated Bundle @ 12hr_Thread 1 Image 2_Hoechst_10X_127.0ms 295 
2-8-08_Rotated Bundle @ 12hr_Thread 1 Image 3_Hoechst_10X_127.0ms 321 
2-8-08_Rotated Bundle @ 12hr_Thread 1 Image 4_Hoechst_10X_127.0ms 352 
2-18-08_Rotated Lg Dia. Bundle 12 HOURS_ Thread 1 Image 1_Hoechst_10X_147.0ms (2-
18-0~1) 359 
2-18-08_Rotated Lg Dia. Bundle 12 HOURS_ Thread 1 Image 2_Hoechst_10X_147.0ms (2-
18-0~2) 368 
2-18-08_Rotated Lg Dia. Bundle 12 HOURS_ Thread 1 Image 3_Hoechst_10X_147.0ms (2-
18-0~3) 406 
2-18-08_Rotated Lg Dia. Bundle 12 HOURS_ Thread 1 Image 4_Hoechst_10X_147.0ms (2-
18-0~4) 348 
2-18-08_Rotated Lg Dia. Bundle 12 HOURS_ Thread 2 Image 1_Hoechst_10X_61.2ms (2-
18-0~1) 246 
2-18-08_Rotated Lg Dia. Bundle 12 HOURS_ Thread 2 Image 2_Hoechst_10X_61.2ms (2-
18-0~2) 357 
2-18-08_Rotated Lg Dia. Bundle 12 HOURS_ Thread 3 Image 1_Hoechst_10X_61.2ms (2-
18-0~1) 490 
2-18-08_Rotated Lg Dia. Bundle 12 HOURS_ Thread 3 Image 2_Hoechst_10X_61.2ms (2-
18-0~2) 451 
2-18-08_Rotated Lg Dia. Bundle 12 HOURS_ Thread 3 Image 3_Hoechst_10X_61.2ms (2-
18-0~3) 404 
2-18-08_Rotated Lg Dia. Bundle 12 HOURS_ Thread 3 Image 4_Hoechst_10X_61.2ms (2-
18-0~4) 343 
2-18-08_Rotated Lg Dia. Bundle 12 HOURS_ Thread 3 Image 5_Hoechst_10X_61.2ms (2-
8720~1) 438 
2-18-08_Rotated Lg Dia. Bundle 12 HOURS_ Thread 3 Image 6_Hoechst_10X_61.2ms (2-
8726~1) 457 
2-25-08_Rotated 12 Hr_ Thread 1 Image 1_Hoechst_10X_99.6ms 410 
2-25-08_Rotated 12 Hr_ Thread 1 Image 2_Hoechst_10X_99.6ms 348 
2-25-08_Rotated 12 Hr_ Thread 1 Image 3_Hoechst_10X_99.6ms 343 
2-25-08_Rotated 12 Hr_ Thread 1 Image 4_Hoechst_10X_99.6ms 363 
2-25-08_Rotated 12 Hr_ Thread 1 Image 5_Hoechst_10X_99.6ms 421 
2-25-08_Rotated 12 Hr_ Thread 1 Image 6_Hoechst_10X_99.6ms 361 
2-25-08_Rotated 12 Hr_ Thread 1 Image 7_Hoechst_10X_99.6ms 353 
2-25-08_Rotated 12 Hr_ Thread 1 Image 8_Hoechst_10X_99.6ms 406 
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2-25-08_Rotated 12 Hr_ Thread 1 Image 9_Hoechst_10X_99.6ms 410 
2-25-08_Rotated 12 Hr_ Thread 2 Image 1_Hoechst_10X_99.6ms 307 
2-25-08_Rotated 12 Hr_ Thread 2 Image 2_Hoechst_10X_99.6ms 337 
2-25-08_Rotated 12 Hr_ Thread 2 Image 3_Hoechst_10X_99.6ms 404 
2-25-08_Rotated 12 Hr_ Thread 2 Image 4_Hoechst_10X_99.6ms 415 
2-25-08_Rotated 12 Hr_ Thread 2 Image 5_Hoechst_10X_99.6ms 384 
2-25-08_Rotated 12 Hr_ Thread 3 Image 1_Hoechst_10X_99.6ms 335 
2-25-08_Rotated 12 Hr_ Thread 3 Image 2_Hoechst_10X_99.6ms 302 
2-25-08_Rotated 12 Hr_ Thread 4 Image 1_Hoechst_10X_99.6ms 444 
2-25-08_Rotated 12 Hr_ Thread 4 Image 2_Hoechst_10X_99.6ms 457 
2-25-08_Rotated 12 Hr_ Thread 4 Image 3_Hoechst_10X_99.6ms 450 
2-25-08_Rotated 12 Hr_ Thread 4 Image 4_Hoechst_10X_99.6ms 431 
2-25-08_Rotated 12 Hr_ Thread 4 Image 5_Hoechst_10X_99.6ms 510 
2-25-08_Rotated 12 Hr_ Thread 4 Image 6_Hoechst_10X_99.6msi 420 
2-25-08_Rotated 12 Hr_ Thread 5 Image 1_Hoechst_10X_99.6ms 452 
2-25-08_Rotated 12 Hr_ Thread 5 Image 2_Hoechst_10X_99.6ms 455 
2-25-08_Rotated 12 Hr_ Thread 5 Image 3_Hoechst_10X_99.6ms 346 
2-18-08_Rotated Lg Dia. Bundle 24 HOURS_ Thread 1 Image 1_Hoechst_10X_50.4ms (2-
18-0~1) 825 
2-18-08_Rotated Lg Dia. Bundle 24 HOURS_ Thread 1 Image 2_Hoechst_10X_50.4ms (2-
18-0~2) 636 
2-18-08_Rotated Lg Dia. Bundle 24 HOURS_ Thread 1 Image 3_Hoechst_10X_50.4ms (2-
18-0~3) 515 
2-18-08_Rotated Lg Dia. Bundle 24 HOURS_ Thread 1 Image 4_Hoechst_10X_50.4ms (2-
18-0~4) 478 
2-18-08_Rotated Lg Dia. Bundle 24 HOURS_ Thread 2 Image 1_Hoechst_10X_50.4ms (2-
18-0~1) 578 
2-18-08_Rotated Lg Dia. Bundle 24 HOURS_ Thread 2 Image 2_Hoechst_10X_50.4ms (2-
18-0~2) 508 
2-18-08_Rotated Lg Dia. Bundle 24 HOURS_ Thread 2 Image 3_Hoechst_10X_50.4ms (2-
18-0~3) 446 
2-18-08_Rotated Lg Dia. Bundle 24 HOURS_ Thread 2 Image 4_Hoechst_10X_50.4ms (2-
18-0~4) 463 
2-18-08_Rotated Lg Dia. Bundle 24 HOURS_ Thread 2 Image 5_COUNTING 
PICTURE_Hoechst_10X_26.7ms (2-419F~1) 448 
2-18-08_Rotated Lg Dia. Bundle 24 HOURS_ Thread 3 Image 1_Hoechst_10X_50.4ms (2-
441B~1) 447 
2-18-08_Rotated Lg Dia. Bundle 24 HOURS_ Thread 3 Image 2_Hoechst_10X_50.4ms (2-
519B~1) 460 
2-4195~1 486 
2-5199~1 434 
2-18-0~1 (2-18-08_Rotated Lg Dia. Bundle 24 HOURS_ Thread 3 Image 1_Hoechst_10X) 377 
2-18-0~2 (2-18-08_Rotated Lg Dia. Bundle 24 HOURS_ Thread 3 Image 2_Hoechst_10X) 388 
2-18-0~3 (2-18-08_Rotated Lg Dia. Bundle 24 HOURS_ Thread 3 Image 3_Hoechst_10X) 316 
2-25-08_Rotated 24 Hr_ Thread 1 Image 1_Hoechst_10X_99.6ms 415 
2-25-08_Rotated 24 Hr_ Thread 1 Image 2_Hoechst_10X_99.6ms 408 
2-25-08_Rotated 24 Hr_ Thread 1 Image 3_Hoechst_10X_99.6ms 444 
2-25-08_Rotated 24 Hr_ Thread 1 Image 4_Hoechst_10X_99.6ms 259 
2-25-08_Rotated 24 Hr_ Thread 1 Image 5_Hoechst_10X_99.6ms 285 
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2-25-08_Rotated 24 Hr_ Thread 1 Image 6_Hoechst_10X_99.6ms 227 
2-25-08_Rotated 24 Hr_ Thread 2 Image 1_Hoechst_10X_99.6ms 320 
2-25-08_Rotated 24 Hr_ Thread 2 Image 2_Hoechst_10X_99.6ms 347 
2-25-08_Rotated 24 Hr_ Thread 2 Image 3_Hoechst_10X_99.6ms 372 
2-25-08_Rotated 24 Hr_ Thread 2 Image 4_Hoechst_10X_99.6ms 320 
2-25-08_Rotated 24 Hr_ Thread 2 Image 5_Hoechst_10X_99.6ms 329 
2-25-08_Rotated 24 Hr_ Thread 2 Image 6_Hoechst_10X_99.6ms 359 
2-25-08_Rotated 24 Hr_ Thread 3 Image 1_Hoechst_10X_99.6ms 309 
2-25-08_Rotated 24 Hr_ Thread 3 Image 2_Hoechst_10X_99.6ms 352 
2-25-08_Rotated 24 Hr_ Thread 3 Image 3_Hoechst_10X_99.6ms 342 
2-25-08_Rotated 24 Hr_ Thread 3 Image 4_Hoechst_10X_99.6ms 349 
2-25-08_Rotated 24 Hr_ Thread 3 Image 5_Hoechst_10X_99.6ms 286 
2-25-08_Rotated 24 Hr_ Thread 3 Image 6_Hoechst_10X_99.6ms 319 
2-25-08_Rotated 24 Hr_ Thread 4 Image 1_Hoechst_10X_99.6ms 338 
2-25-08_Rotated 24 Hr_ Thread 4 Image 2_Hoechst_10X_99.6ms 288 
2-25-08_Rotated 24 Hr_ Thread 4 Image 3_Hoechst_10X_99.6ms 399 
2-25-08_Rotated 24 Hr_ Thread 4 Image 4_Hoechst_10X_99.6ms 311 
2-25-08_Rotated 24 Hr_ Thread 5 Image 1_Hoechst_10X_99.6ms 286 
2-25-08_Rotated 24 Hr_ Thread 5 Image 2_Hoechst_10X_99.6ms 377 
2-25-08_Rotated 24 Hr_ Thread 5 Image 3_Hoechst_10X_99.6ms 323 
2-25-08_Rotated 24 Hr_ Thread 5 Image 4_Hoechst_10X_99.6ms 317 
2-25-08_Rotated 24 Hr_ Thread 5 Image 5_Hoechst_10X_99.6ms 305 
2-8-08_Rotated Bundle @ 48hr_Thread 1 Image 1_Hoechst_10X_127.0ms 309 
2-8-08_Rotated Bundle @ 48hr_Thread 1 Image 2_Hoechst_10X_127.0ms 272 
2-18-08_Rotated Lg Dia. Bundle 48 HOURS_ Thread 1 Image 1_Hoechst_10X_50.3ms (2-
18-0~1) 341 
2-18-08_Rotated Lg Dia. Bundle 48 HOURS_ Thread 1 Image 2_Hoechst_10X_50.3ms (2-
18-0~2) 292 
2-18-08_Rotated Lg Dia. Bundle 48 HOURS_ Thread 2 Image 1_Hoechst_10X_50.3ms (2-
18-0~1) 291 
2-18-08_Rotated Lg Dia. Bundle 48 HOURS_ Thread 2 Image 2_Hoechst_10X_50.3ms (2-
18-0~2) 444 
2-18-08_Rotated Lg Dia. Bundle 48 HOURS_ Thread 2 Image 3_Hoechst_10X_50.3ms (2-
18-0~3) 377 
2-25-08_Rotated 48 Hr_ Thread 1 Image 2 _Hoechst_10X_127.0ms 491 
2-25-08_Rotated 48 Hr_ Thread 1 Image 3 _Hoechst_10X_127.0ms 450 
2-25-08_Rotated 48 Hr_ Thread 1 Image _Hoechst_10X_127.0ms 485 
2-25-08_Rotated 48 Hr_ Thread 2 Image 1 _Hoechst_10X_127.0ms 350 
2-25-08_Rotated 48 Hr_ Thread 2 Image 2 _Hoechst_10X_127.0ms 375 
2-25-08_Rotated 48 Hr_ Thread 2 Image 3 _Hoechst_10X_127.0ms 375 
2-25-08_Rotated 48 Hr_ Thread 2 Image 4 _Hoechst_10X_127.0ms 360 
2-25-08_Rotated 48 Hr_ Thread 3 Image 1 _Hoechst_10X_127.0ms 264 
2-25-08_Rotated 48 Hr_ Thread 3 Image 2 _Hoechst_10X_127.0ms 390 
2-25-08_Rotated 48 Hr_ Thread 3 Image 3 _Hoechst_10X_127.0ms 307 
2-25-08_Rotated 48 Hr_ Thread 3 Image 4 _Hoechst_10X_127.0ms 291 
2-25-08_Rotated 48 Hr_ Thread 3 Image 5 _Hoechst_10X_127.0ms 326 
2-25-08_Rotated 48 Hr_ Thread 3 Image 6 _Hoechst_10X_127.0ms 315 
2-25-08_Rotated 48 Hr_ Thread 4 Image 1 _Hoechst_10X_127.0ms 331 
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2-25-08_Rotated 48 Hr_ Thread 4 Image 2 _Hoechst_10X_127.0ms 297 
2-25-08_Rotated 48 Hr_ Thread 4 Image 3 _Hoechst_10X_127.0ms 311 
2-25-08_Rotated 48 Hr_ Thread 4 Image 4 _Hoechst_10X_127.0ms 495 
2-25-08_Rotated 48 Hr_ Thread 4 Image 5 _Hoechst_10X_127.0ms 321 
2-25-08_Rotated 48 Hr_ Thread 5 Image 1 _Hoechst_10X_127.0ms 292 
2-25-08_Rotated 48 Hr_ Thread 5 Image 2 _Hoechst_10X_127.0ms 294 
2-25-08_Rotated 48 Hr_ Thread 5 Image 3 _Hoechst_10X_127.0ms 448 
2-25-08_Rotated 48 Hr_ Thread 5 Image 4_Hoechst_10X_127.0ms 303 
2-11-08_Rotated LARGE DIA. Bundle 24 hr_Thread 1 Image 1_Hoechst_10X_305.0ms 334 
2-11-08_Rotated LARGE DIA. Bundle 24 hr_Thread 1 Image 2_Hoechst_10X_196.6ms 418 
2-11-08_Rotated LARGE DIA. Bundle 24 hr_Thread 1 Image 3_Hoechst_10X_45.7ms 506 
2-11-08_Rotated LARGE DIA. Bundle 24 hr_Thread 1 Image 4_Hoechst_10X_81.9ms 477 
2-11-08_Rotated LARGE DIA. Bundle 24 hr_Thread 2 Image 1_Hoechst_10X_50.4ms 338 
2-11-08_Rotated LARGE DIA. Bundle 24 hr_Thread 2 Image 2_Hoechst_10X_50.4ms 321 
2-11-08_Rotated LARGE DIA. Bundle 24 hr_Thread 2 Image 3_Hoechst_10X_50.4ms 392 
2-11-08_Rotated LARGE DIA. Bundle 24 hr_Thread 2 Image 4_Hoechst_10X_50.4ms 412 
2-11-08_Rotated LARGE DIA. Bundle 24 hr_Thread 2 Image 5_Hoechst_10X_50.4ms 347 
2-11-08_Rotated LARGE DIA. Bundle 24 hr_Thread 2 Image 6_Hoechst_10X_50.4ms 431 
2-11-08_Rotated LARGE DIA. Bundle 24 hr_Thread 2 Image 7_Hoechst_10X_50.4ms 436 
2-11-08_Rotated LARGE DIA. Bundle 24 hr_Thread 2 Image 8_Hoechst_10X_50.4ms 361 
2-11-08_Rotated LARGE DIA. Bundle 24 hr_Thread 2 Image 9_Hoechst_10X_11.8ms 266 
2-11-08_Rotated LARGE DIA. Bundle 24 hr_Thread 3 Image10_Hoechst_10X_50.4ms 295 
2-11-08_Rotated LARGE DIA. Bundle 24 hr_Thread 3 Image 1_Hoechst_10X_50.4ms 232 
2-11-08_Rotated LARGE DIA. Bundle 24 hr_Thread 3 Image 2_Hoechst_10X_50.4ms 277 
2-11-08_Rotated LARGE DIA. Bundle 24 hr_Thread 3 Image 3_Hoechst_10X_50.4ms 396 
2-11-08_Rotated LARGE DIA. Bundle 24 hr_Thread 3 Image 4_Hoechst_10X_50.4ms 353 
2-11-08_Rotated LARGE DIA. Bundle 24 hr_Thread 3 Image 5_Hoechst_10X_50.4ms 388 
2-11-08_Rotated LARGE DIA. Bundle 24 hr_Thread 3 Image 6_Hoechst_10X_50.4ms 387 
2-11-08_Rotated LARGE DIA. Bundle 24 hr_Thread 3 Image 7_Hoechst_10X_50.4ms 368 
2-11-08_Rotated LARGE DIA. Bundle 24 hr_Thread 3 Image 8_Hoechst_10X_50.4ms 508 
2-11-08_Rotated LARGE DIA. Bundle 24 hr_Thread 3 Image 9_Hoechst_10X_50.4ms 326 
2-11-08_Rotated SMALL DIA. Bundle 24 hr_Thread 1 Image 1_Hoechst_10X_37.4ms 246 
2-11-08_Rotated SMALL DIA. Bundle 24 hr_Thread 1 Image 2_Hoechst_10X_12.9ms 125 
2-11-08_Rotated SMALL DIA. Bundle 24 hr_Thread 1 Image 3_Hoechst_10X_12.9ms 221 
2-11-08_Rotated SMALL DIA. Bundle 24 hr_Thread 2 Image 1_Hoechst_10X_23.1ms 226 
2-11-08_Rotated SMALL DIA. Bundle 24 hr_Thread 3 Image 1_Hoechst_10X_23.1ms 211 
2-11-08_Rotated SMALL DIA. Bundle 24 hr_Thread 3 Image 2_Hoechst_10X_23.1ms 225 
2-11-08_Rotated SMALL DIA. Bundle 24 hr_Thread 3 Image 3_Hoechst_10X_23.1ms 252 
2-11-08_Rotated SMALL DIA. Bundle 24 hr_Thread 3 Image 4_Hoechst_10X_23.1ms 277 
2-18-08_Rotated Sm. Dia. Bundle 24 HOURS_ Thread 1 Image 1_Hoechst_10X_30.8ms (2-
18-0~1) 266 
2-18-08_Rotated Sm. Dia. Bundle 24 HOURS_ Thread 1 Image 2_Hoechst_10X_30.8ms (2-
18-0~2) 304 
2-18-08_Rotated Sm. Dia. Bundle 24 HOURS_ Thread 1 Image 3_Hoechst_10X_30.8ms (2-
18-0~3) 373 
2-18-08_Rotated Sm. Dia. Bundle 24 HOURS_ Thread 2 Image 1_Hoechst_10X_30.8ms (2-
18-0~1) 238 
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2-18-08_Rotated Sm. Dia. Bundle 24 HOURS_ Thread 2 Image 2_Hoechst_10X_30.8ms (2-
18-0~2) 351 
2-18-08_Rotated Sm. Dia. Bundle 24 HOURS_ Thread 2 Image 3_Hoechst_10X_30.8ms (2-
18-0~3) 349 
2-18-08_Rotated Sm. Dia. Bundle 24 HOURS_ Thread 2 Image 4_Hoechst_10X_30.8ms (2-
18-0~4) 325 
2-18-08_Rotated Sm. Dia. Bundle 24 HOURS_ Thread 1 Image 2_Hoechst_10X_30.8ms-1 
(2-18-0~1) 280 
2-18-08_Rotated Sm. Dia. Bundle 24 HOURS_ Thread 1 Image 3_Hoechst_10X_30.8ms-
1(2-18-0~2) 303 
Average 363 
Standard Deviation 87 
Table 17. Average diameter for hydrated bundles of ten fibrin microthreads. 
 
Experiment Image 
Diameter 
(µm) 
1-19-07_Thread 1_Image 1_Bundled 5 Rotated_Hoechst dye_10X_429.2ms 175 
1-19-07_Thread 1_Image 2_Bundled 5 Rotated_Hoechst dye_10X_429.2ms 187 
1-19-07_Thread 1_Image 3_Bundled 5 Rotated_Hoechst dye_10X_429.2ms 186 
1-19-08_Rotated Bundles of 5_Thread 1 Image 1_Hoechst_10X_370.8ms 204 
1-19-08_Rotated Bundles of 5_Thread 1 Image 2_Hoechst_10X_370.8ms 197 
1-19-08_Rotated Bundles of 5_Thread 1 Image 3_Hoechst_10X_370.8ms 183 
1-19-08_Rotated Bundles of 5_Thread 1 Image 4_Hoechst_10X_370.8ms 159 
1-19-08_Rotated Bundles of 5_Thread 2 Image 1_Hoechst_10X_370.8ms 258 
1-19-08_Rotated Bundles of 5_Thread 2 Image 2_Hoechst_10X_370.8ms 263 
1-19-08_Rotated Bundles of 5_Thread 2 Image 3_Hoechst_10X_370.8ms 233 
1-19-07_Thread 3_Image 3_Bundled 5 Rotated_Hoechst dye_10X_305.0ms 233 
2-1-08_Rotated Bundle of 5_Thread 1 Image 1_Hoechst_10X_196.6ms.tif 179 
2-1-08_Rotated Bundle of 5_Thread 1 Image 2_Hoechst_10X_196.6ms 371 
2-1-08_Rotated Bundle of 5_Thread 2 Image 1_Hoechst_10X_196.6ms.tif 277 
2-1-08_Rotated Bundle of 5_Thread 2 Image 2_Hoechst_10X_196.6ms.tif 208 
2-1-08_Rotated Bundle of 5_Thread 3 Image 2_Hoechst_10X_196.6ms.tif 169 
Average 218 
Standard Deviation 54 
Table 18. Average diameter for hydrated bundles of five fibrin microthreads. 
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Experiment Image 
Diameter 
(µm) 
11-28-07_Droplet_thread 4_5X_250.9ms (10X) 106 
11-28-07_Droplet_thread 4_10X_161.9ms (20X) 106 
11-28-07_Droplet_thread 6_5X_250.9ms (10X) 174 
11-28-07_Droplet_thread 6_10X_139.9ms (20X) 169 
12-12-07_Droplet_Bundled_thread 1_5X_983.9ms  (10X) 114 
12-12-07_Droplet_Bundled_thread 2_5X_983.9ms (10X) 171 
12-12-07_Droplet_Bundled_thread 2_10X_770.9ms (20X) 144 
11-28-07_Rotator_thread 4 Area 1_5X_699.3ms 90 
11-28-07_Rotator_thread 4 Area 1_10X_32.3ms  108 
11-28-07_Rotator_thread 4 Area 1_10X_139.9ms 96 
11-28-07_Rotator_thread 4 Area 2_5X_408.9ms 105 
11-28-07_Rotator_thread 4 Area 3_10X_86.0ms 96 
11-28-07_Rotator_thread 4 Area 3_10X_187.3ms  (5X) 87 
11-28-07_Rotator_thread 5_5X_86.0ms 98 
11-28-07_Rotator_thread 5_10X_86.0ms 107 
11-28-07_Rotator_thread 6 Area 1_5X_86.0ms 148 
11-28-07_Rotator_thread 6 Area 1_10X_86.0ms 149 
11-28-07_Rotator_thread 6 Area 2 (Left)_10X_86.0ms 141 
11-28-07_Rotator_thread 6 Area 2 (Right)_10X_86.0ms 188 
11-28-07_Rotator_thread 6 Area 2_5X_86.0ms 183 
12-12-07_Rotation_Bundled_thread 1_5X_1.5s 100 
12-12-07_Rotation_Bundled_thread 2_5X_937.1ms 88 
12-12-07_Rotation_Bundled_thread 1_10X_473.1ms 102 
12-12-07_Rotation_Bundled_thread 2_10X_473.1ms 103 
1-19-08_Rotated Bundles of 3_Thread 1 Image 1_Hoechst_10X_370.8ms-1 113 
1-19-08_Rotated Bundles of 3_Thread 2 Image 1_Hoechst_10X_370.8ms 117 
1-19-08_Rotated Bundles of 3_Thread 3 Image 1_Hoechst_10X_370.8ms:Blue 211 
2-1-08_Rotated Bundle of 3_Thread 1 Image 1_Hoechst_10X_276.6ms.tif 149 
2-1-08_Rotated Bundle of 3_Thread 1 Image 2_Hoechst_10X_276.6ms.tif 259 
2-1-08_Rotated Bundle of 3_Thread 2 Image 1_Hoechst_10X_196.6ms 342 
2-1-08_Rotated Bundle of 3_Thread 3 Image 1_Hoechst_10X_196.6ms 170 
Average 140 
Standard Deviation 56 
Table 19. Average diameter for hydrated bundles of three fibrin microthreads. 
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Appendix E: Design Alternatives 
Potential designs 
D1 – Dynamic seeding (rotation seeding), cell adhesion molecule, bundled biological 
microthreads 
D2 – Static seeding (droplet method), cell adhesion molecule 
D3 – Dynamic seeding (rotation seeding), surface modification (microgrooves) 
D4 – Static Seeding (droplet method), surface modification 
 
Objectives (O) 
The objectives selected for comparing design alerntatives were the top seven objectives 
from Table 14. 
O1 – Increase cell density 
O2 – Maintain mechanical Integrity of biological microthreads 
O3 – Strength of cell attachment 
O4 – Number of cells attached 
O5 – Maximize cell quantity on biological microthreads 
O6 – Control quantity of cells delivered 
O7 – Increase speed of ‘more density’ 
 
 
Objectives 
& 
Constraints 
↓ 
 
Design → Weight D1 D2 D3 D4 
C: Maintain Mechanical 
Integrity 
Y/N Y Y Y Y 
C: Cost effective Y/N Y Y Y Y 
O1 .133 2(.133)=.266 1(.133)=.133 2(.133)=.266 1(.133)=.133 
O2 .108 1(.108)=.108 2(.108)=.216 0(.108)=.0 2(.108)=.216 
O3 .117 2(.117)=.234 0(.117)=0 2(.117)=.234 0(.117)=0 
O4 .123 2(.123)=.246 1(.123)=.123 1(.123)=.123 1(.123)=.123 
O5 .123 2(.123)=.246 1(.123)=.123 1(.123)=.123 2(.123)=.246 
O6 .106 1(.106)=.106 1(.106)=.106 1(.106)=.106 1(.106)=.106 
O7 .127 1(.127)=.127 0(.127)=0 1(.127)=.127 0(.127)=0 
Total  1.333 .701 .979 .824 
Table 20. Design alternative comparison based off of weighted objectives from Table 14. 
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Objectives 
 
O1 O2 O3 O4 O5 O6 O7 Total 
Objective 
Weights 
 
.133 .108 .117 .123 .123 .106 .127  
Cell Adhesion 
Molecules  
2(.133)= 
.266 
0(.108)= 
0 
1(.117)= 
.117 
2(.123)= 
.246 
1(.123)= 
.123 
1(.106)= 
.106 
1(.127)= 
.127 
.985 
Dynamic 
Seeding 
Technique  
2(.133)= 
.266 
2(.108)= 
.216 
2(.117)=  
.234 
2(.123)= 
.246 
2(.123)= 
.246 
2(.106)= 
.212 
2(.127)= 
.254 
1.67 
Physical 
Surface 
Alteration  
2(.133)= 
.266 
1(.108)= 
.108 
1(.117)= 
.117 
2(.123)= 
.246 
2(.123)= 
.246 
1(.106)= 
.106 
0(.127)= 
0 
1.09 
Table 21. Candidate methods to increase cell density on fibrin microthreads. 
 
Objectives 
 
O1 O2  O3 O4 O5 O6 O7 Total 
Objective 
Weights 
 
.133 .108 .117 .123 .123 .106 .127  
Stirred  1(.133)= 
.133 
0(.108)= 
0 
1(.117)= 
.117 
1(.123)= 
.123 
1(.123)= 
.123 
0(.106)= 
0 
1(.127)= 
.127 
.683 
Centrifugation 1(.133)= 
.133 
0(.108)= 
0 
0(.117)= 
0 
0(.123)= 
0 
1(.123)= 
.123 
0(.106)= 
0 
2(.127)= 
.154 
.410 
Rotation 2(.133)= 
.266 
1(.108)= 
.108 
2(.117)= 
.234 
2(.123)= 
.246 
2(.123)= 
.246 
2(.106)= 
.212 
1(.127)= 
.127 
1.44 
Table 22. Candidate dynamic seeding techniques to increase cell density on fibrin microthreads. 
 
Objectives 
 
O1 O2  O3 O4 O5 O6 O7 Total 
Objective 
Weights 
 
.133 .108 .117 .123 .123 .106 .127  
Bundling of 
microthreads 
2(.133)= 
.266 
1(108)=  
.108 
2(.117)= 
.234 
1(.123)= 
.123 
2(.123)= 
.246 
1(.106)= 
.106 
2(.127)= 
.254 
1.34 
Electrospray 
onto 
microthreads 
1(.133)= 
.133 
0(.108)= 
0 
0(.117)= 
0 
1(.123)= 
.123 
0(.123)= 
0 
0(.106)= 
0 
0(.127)= 
0 
.256 
Patterned 
microgrooves 
on 
microthreads 
1(.133)= 
.133 
0(.108)= 
0 
1(.117)= 
.117 
1(.123)= 
.123 
1(.123)= 
.123 
1(.106)= 
.106 
0(.127)= 
.127 
.729 
Table 23. Candidate physical surface alterations to increase cell density on fibrin microthreads. 
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Objectives 
 
O1 O2  O3 O4 O5 O6 O7 Total 
Objective 
Weights 
 
.133 .108 .117 .123 .123 .106 .127  
Fibronectin 2(.133)= 
.266 
1(108)=  
.108 
2(.117)= 
.234 
1(.123)= 
.123 
2(.123)= 
.246 
1(.106)= 
.106 
2(.127)= 
.254 
1.34 
RGD peptides 1(.133)= 
.133 
0(.108)= 
0 
1(.117)= 
.117 
1(.123)= 
.123 
1(.123)= 
.123 
1(.106)= 
.106 
0(.127)= 
.127 
.729 
Collagen 1(.133)= 
.133 
1(.108)= 
.108 
1(.117)= 
.117 
1(.123)= 
.123 
0(.123)= 
0 
1(.106)= 
.106 
1(.127)= 
.127 
.714 
Laminin 0(.133)= 
0 
2(.108)= 
.216 
1(.117)= 
.117 
1(.123)= 
.123 
0(.123)= 
0 
0(.106)= 
0 
0(.127)= 
0 
.456 
Table 24. Candidate cell adhesion molecules to increase cell density on fibrin microthreads. 
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Appendix F: Cell Culture Protocol 
Thawing hMSCs 
 
Materials 
1.  DMEM (Dulbecco’s Modified Eagle’s Medium), 10% FBS, 1% P/S 
with all supplements (serum = FBS, L-glutamine, antibiotics = P/S), 37C.  
Stored at 4C (DMEM) & -5 to -20C (FBS, P/S). 
 
2. Pipets: 25mL, 10mL, 5mL Serological Pipets. 
 
3. Miscellaneous items: Sterile culture flasks, 15mL conical tubes, 70% Isopropyl 
Alcohol (IPA), Pipet Aid, Lab marker for labeling. 
 
Procedure 
1. Spray inside surface of hood with 70% IPA.  Spray all exterior surfaces of containers 
to be brought into hood with 70% IPA.  Set up all necessary items in hood.   
 
2. Remove stored cryovial(s) containing cells from Liquid Nitrogen cryotank/Dry ice. 
Optional: Wipe cryovial(s) with 70% IPA and in sterile field, brefly twist cap a quarter 
turn to relieve pressure, then retighten.  
 
3. Thaw cells rapidly by immediately immersing vial(s) into 37° C water bath.  Do not 
submerge them completely and watch them closely. Gently agitate for approx. 2 min (no 
longer than 3 min). Note: Most cell death occurs between –50° C and 0° C when thawing. 
 
4. When fully thawed (all ice crystals melted), remove vial(s) immediately, wipe dry then 
spray outside of vial(s) thoroughly with 70% IPA before bringing cells into the hood. 
Transfer thawed cell suspension into 15mL tube containing 5mL pre-warmed media to 
dilute.   
 
5. Centrifuge cells at 500-600rpm for 5 minutes to remove any residual DMSO. 
While cells are being spun down, set up new flasks and add appropriate amount of 
DMEM to each: ~2-5mL for T25, ~12-15mL for T75. Temperature equilibrate to 37° C. 
 
6. Decant supe; Resuspend cell pellet in minimum volume of fresh pre-warmed media. 
Perform CELL COUNTING. seed cells by transferring the appropriate amount of cell 
suspension into new culture flask(s) with fresh medium.  Note: Amount of suspension 
transferred will depend on the density at which cells were frozen and desired cell density 
for new seed. 
 
7. Place cells in incubator, and replace with equal volume of fresh medium after 24 hrs to 
remove any (floating) dead cells. Observe cells daily for growth (confluency reached by 
~1 week) and freedom from contamination. Media to be changed every 3-4 days. 
 
8. Clean up hood and spray down surface with 70% IPA. Close it and turn on UV light.
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Cell Subculture 
 
Materials 
1.  DMEM (Dulbecco’s Modified Eagle’s Medium), 10% FBS, 1% P/S 
with all supplements (serum = FBS, L-glutamine, antibiotics = P/S), 37C.  
Stored at 4C (DMEM) & -5 to -20C (FBS, P/S). 
 
2. DPBS, 37C. Stored at RT. 
 
3. 0.25% Trypsin, 37C. Stored at -20C.  (Not to be left in water bath for extended period 
of time.) 
 
4. Pipets: 25mL, 10mL, 5mL Serological Pipets, 5mL aspirating Pasteur Pipets.  
 
5. Miscellaneous items: Sterile culture flasks for seeding, 70% Isopropyl Alcohol (IPA), 
Pipet Aid, Lab marker for labeling. 
 
 
Procedure 
1. Spray inside surface of hood with 70% IPA.  Spray all exterior surfaces of containers 
to be brought into hood with 70% IPA.  Set up all necessary items in hood.   
 
2. Remove all media from culture dish/flask. 
 
3. Add sterile DPBS to flask for ~1min wash: ~2mL for T25, ~5mL for T75. 
Rinse entire bottom surface by gently rocking flask. Remember: Handle flasks vertically 
as to not allow media to enter neck of dish, specially designed for CO2 exchange.  
 
4. Remove (Aspirate) DPBS. 
 
5. Add Trypsin: ~2mL for T25, ~5mL for T75, gently to bottom edge/corner of flask (as 
to not shock/dislodge cells). Again, rock flask gently to ensure full coating of bottom 
surface. Check cells under microscope to make sure they are detaching from flask and 
have “rounded-up” morphology. (Trypsin is a protease that acts to degrade protein.) 
 
6. Set up new flasks and add appropriate amount of fresh DMEM to each: ~2-5mL for 
T25, ~12-15mL for T75. 
Note: No need to aspirate trypsin since DMEM will inactivate its proteolytic action. 
 
7. When all cells appear round, add DMEM: ~2mL for T25, ~5mL for T75 and 
thoroughly wash flask to gather up all cells from the bottom of the flask by gently 
triturating up and down while tilting the flask. 
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8. Add appropriate volume (depending on % confluency) of cell suspension to fresh 
flasks.  Gently rock/swirl flask to spread out cells.   
 
9. Place cells in incubator and observe daily for growth (toward confluency) and freedom 
from contamination. Media to be changed every 3-4 days. 
 
10. Clean up hood and spray down surface with 70% IPA. Close it and turn on UV light 
 
Cell Counting 
 
Materials 
1. DMEM (Dulbecco’s Modified Eagle’s Medium), 10% FBS, 1% P/S 
with all supplements (serum = FBS, L-glutamine, antibiotics = P/S), 37C.  
Stored at 4C (DMEM) & -5 to -20C (FBS, P/S). 
 
2. DPBS, 37C. Stored at RT. 
 
3. 0.25% Trypsin, 37C.  Stored at -20C.  (Not to be left in water bath for extended period 
of time.) 
 
4. Pipets: 25mL, 10mL, 5mL Serological Pipets, 5mL aspirating Pasteur Pipets.  
 
5. Miscellaneous items: Trypan Blue dye, hemacytometer + coverslip, 70% EtOH, Pipet 
Aid, Eppendorf pipettor and associated tips, Lab marker for labeling. 
 
 
Procedure 
1.  Follow SUBCULTURING hMSCs protocol for a T75 flask of cells. 
 
2. After trypsinizing hMSCs, place DMEM (~5mL) + Trypsin (~5mL) + cells into 15mL 
centrifuge tube.  
 
3. Centrifuge at 600rpm for 5min @ RT. 
  
4. Decant supernatant; Resuspend pellet in ~1mL DMEM.  
 
5. Prepare a 1:10 dilution (thus dilution factor = 10) of cell suspension to be counted as 
follows:  
 
Place 50 µL Trypan Blue + 40 µL non-sterile DPBS + 10 µL in a small Eppendorf tube. 
Triturate gently as to increase accuracy of count.  
Note: Trypan Blue is toxic and a potential carcinogen so extra care should be taken with 
its use. 
 
79 
 
6. Prepare the hemacytometer by placing a clean coverslip onto its center grid section 
(mirror-like polished surface with wells).  Both should be cleaned with ethanol prior to 
use.  
 
7. Carefully load a small amount (~10µL) of cell suspension into the wells underneath 
and on each end of the coverslip.   
Note: A hemacytometer is a specialized glass slide with a 3x3 grid pattern etched upon it 
whose volume is known. When covered by a coverslip, cells spread out due to capillary 
action. 
 
8.  Using a microscope, cells are counted within each of squares of the hemacytometer 
grid to obtain a measure of cell concentration as follows: 
                                                  
 
 
Count all viable cells in each of the 4 corner fields adjacent to the center square (i.e. 
squares that lie along a diagonal, here 1, 3, 7 & 9) for each side of hemacytometer for a 
total of 8 fields.  Adopt a rule for counting cells that fall on grid lines to eliminate 
duplicate counts (i.e. count cells on left or top lines of a square, but not those on bottom 
or right lines).  
Note: Dead cells appear blue as stained by Trypan Blue and should be excluded from the 
count, while viable cells appear bright and do not take up the dye unless exposed to it for 
an extended period of time after which they may absorb it and appear non-viable.   
 
9. Use the following equations with numbers attained from count to calculate cell 
concentrations. 
 
Final count or actual cell density in cells/mL   Eqn:  C1V1 = C2V2 
 
                      average count per field 
#  viable cells / mL  =  [# viable cells / total # fields]   X   dilution factor   X   104 
           
total # viable cells  =  #  viable cells / mL   X   original vol from which sample removed  
         =  C1             X         V1 
 
final resuspension volume (# mL of cells to add)  =  total # cells / target cell density or [] 
          V2 = C1V1                /                C2 
 
% viability  =  total # viable cells / total # cells   X   100  
Note: Must perform dead count for total # cells. 
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Appendix G: MTS Sensitivity and Results 
As can be seen below in Figure 23, the MTS assay was not sensitive enough for low cell 
counts which were found on the fibrin microthreads. This can be seen through the large 
standard deviation and negative cell concentration for droplet seeding with individual 
thick fibrin microthreads.  
MTS Results
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Figure 23. MTS results not sensitive to low cell counts on fibrin microthreads 
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Figure 24. Concentration vs. absorbance for MTS results
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Appendix H: Glossary and Acronyms 
 
Acronyms 
MI: Myocardial infarction 
hMSC: Human mesenchymal stem cell 
ECM: Extracellular matrix 
Fn: Fibronectin 
RGD: Arginine-glycine-aspartate 
FBS: Fetal bovine serum 
DPBS: Dulbecco’s phosphate buffered saline 
PE: Polyethylene 
ID: Inner diameter 
OD: Outer diameter 
 
Glossary  
Adhesion molecules- Proteins used to increase cell attachment to the surface of fibrin 
microthreads.  
 
Adult stem cell- Undifferentiated cell that can renew itself and differentiate into the 
specialized cell types of a tissue or organ. 
 
Bundled microthreads- Discrete fibrin microthreads can be bundled to make intricate 
structures with microgrooves between the fibrin threads. 
 
Cardiac regeneration- Applying tissue engineering, stem cell therapy, medical devices 
and other techniques to repair damaged or diseased areas of the heart. 
 
Cell-based cardiac repair- The use of cells as a method of treating cardiovascular diseases 
such as MI and heart failure.  
 
Cell seeding- Method by which cells are transferred from a flask to the platform of 
interest. 
 
Droplet seeding- A static cell seeding technique in which fibrin microthreads are adhered 
to a washer and a drop of cells is placed on the washer and gravity allows for the cells to 
attach to the fibrin microthread. 
 
Dynamic seeding- Involves stirring or agitation of cells in suspension together with the 
scaffold. 
 
Fibrin- A natural biomaterial that is biocompatible, bioresorbable, and essential in normal 
wound healing. 
 
Fibrin microthread- Biological microthreads produced by coextruding solutions of 70 
mg/mL fibrinogen and 6 U/mL thrombin through small diameter polyethylene tubing. 
82 
 
These biological microthreads have the potential for cell-mediated tissue ingrowth and 
regeneration. 
 
Fibronectin- An ECM protein, that participates in a number of cellular processes 
including tissue repair, wound healing, and cell migration/adhesion 
 
Heart- The organ that pumps the oxygenated blood and nutrients, via the aorta, 
throughout the body. 
 
Heart failure- A condition that can result from any structural or functional cardiac 
disorder that impairs the ability of the heart to fill with or pump a sufficient amount of 
blood through the body. 
 
Human mesenchymal stem cell- An adult stem cells found in bone marrow. 
 
Ischemia- A restriction in blood and oxygen supply that can result in the damage of 
tissue. 
 
Microthread suturing- A method in which fibrin microthreads can transplant stem cells 
into an infarcted area of the heart.  
 
Myocardial infarction- Necrosis of a region of the myocardium; can potentially lead to 
heart failure. 
 
Rotational seeding- A dynamic cell seeding technique in which fibrin  microthreads 
contained in Silastic tubing are rotated vertically around a horizontal axis while being 
suspended in cell suspension. 
 
Static seeding- Cell seeding performed by allowing a cell suspension to statically deposit 
cells on the platform of interest. 
 
 
 
